Top

Ashish M. Kamat, MD, MBBS, FACS

Department of Urology, Division of Surgery

About Dr. Ashish M. Kamat

Ashish M. Kamat, MD, MBBS is an Endowed Professor of Urologic Oncology (Surgery) and Cancer Research at University of Texas MD Anderson Cancer Center. He is also President of the International Bladder Cancer Group (IBCG) and International Bladder Cancer Network (IBCN). He is Associate Editor for European Urology Oncology, Editor for the UroToday Bladder Cancer Center of Excellence, directed the MDACC Urologic Oncology Fellowship from 2005-2016, and is an alumnus of the AUA Leadership Program

Dr. Kamat is recognized internationally as an expert in urologic oncology with an emphasis on bladder cancer, immunotherapy, organ-sparing and minimally invasive techniques. Dr. Kamat maintains an active research portfolio in this area with a focus on efforts to develop novel therapies and diagnostics, and identifying predictors of response to therapy (e.g. intravesical immunotherapy), as a first step towards personalized cancer therapeutics. He has led several national and international studies, which have been reported in high impact journals. Dr. Kamat is an exceptional educator and as Program Director grew the Urologic Oncology Fellowship into the premier program in the US. In 2016, a scholarly endowment was created in honor of Dr Kamat, the "Wayne B. Duddlesten Professorship in Honor of Dr Ashish Kamat" for his work in Cancer Research and Education at MD Anderson. Dr Kamat has over 325 publications, is listed in 'Who's Who in Medicine' and 'Best Doctors in America', and has won the 'Compassionate Doctor Award' from patient groups.

Additionally, Dr. Kamat is on grant review panels of national and international study sections, serves in an advisory capacity to various organizations, such as the National Cancer Institute's (NCI) Bladder Cancer Task Force (BCTF), Society of Immunotherapy for Cancer (SITC); and as an AUA International Faculty. He is a member of the AUA Guidelines Panel for Bladder Cancer.

Primary Appointment

Endowed Professor, Wayne B. Duddlesten Sr. Professorship in Cancer Research, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor (Tenured), Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

Immunotherapy, Personalized Therapeutics, Organ Conservation, Novel therapies, Stem Cell Biology

Education & Training

Degree-Granting Education

1994	Seth G. S. Medical College & King Edward Memorial Hospital, University of Bombay, Bombay, IN, MBBS (MD) in Medicine, Surgery
1994	Educational Committee for Foreign Medical Graduates, Philadelphia, Pennsylvania, US, USMLE in Medicine
1988	University of Bombay Jai Hind College, Bombay, IN, Biologic Sciences, Higher Secondary Certificate (HSC)

Postgraduate Training

2001-2003	Fellowship, Urologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
2000-2001	Chief Resident, Urology, West Virginia University, Morgantown, West Virginia
1997-2000	Residency, Urology, West Virginia University, Morgantown, West Virginia
1995-1997	Internship, General Surgery, West Virginia University, Morgantown, West Virginia

Board Certifications

2015	American Board of Urology

Experience & Service

Administrative Appointments/Responsibilities

Chair, Bladder Cancer Patient Support Center, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present

Director, Bladder Cancer Research Program, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2020 - Present

Associate Cancer Center Director, Reliance Foundation HN Hospital, Mumbai, Maharashtra, 2016 - Present

Other Appointments/Responsibilities

Inaugural Chair, Scientific Advisory Board, World Bladder Cancer Patient Coalition, Brussels, Brussels-Capital Region, 2024 - Present

Co-Chairman, Expert Advisory Committee, Bladder Cancer, World Bladder Cancer Patient Coalition, Brussels, Brussels-Capital Region, 2021 - Present

Scientific Advisory Board External Advisor, Bladder Cancer, Memorial Sloan-Kettering Cancer Center, New York, New York, 2017 - Present

Chair, Peer Reviewed Cancer Research Program (PRCRP), Oncology, U.S. Department of Defense, Fort Detrick, Maryland, 2017 - Present

Consultant, Bladder Cancer, National Cancer Institute (NCI), Bethesda, Maryland, 2010 - Present

Scientific Advisory Board Member, Bladder Cancer, Bladder Cancer Advocacy Network (BCAN), Bethesda, Maryland, 2007 - Present

Invited Member, Scientific Advisory Board, Bladder Cancer WebCafé, 2005 - Present

Institutional Committee Activities

Member, Physician Advisory Council, 2019 - Present

Member, Africa Committee, 2016 - Present

Member, International Advisory Board, 2014 - Present

Advisor, Surgical Services Advisory Committee, 2011 - Present

Member, India Steering Committee, 2008 - Present

Member, Operating Room (OR) Committee, 2003 - Present

Honors & Awards

2024	Sigma Xi Nominated Member, Sigma Xi Scientific Research Honor Society
2021	A.G. Phadke Award for Lifetime Achievement in Urology, Urological Society of India
2017	Inaugural Lecturer - Albert Lectureship in Bladder Cancer, Kansas University
2016	Graduate Medical Education Outstanding Program Director Award (Nominee), The University of Texas MD Anderson Cancer Center
2016	Emil J Freireich Award for Excellence in Education (Nominee), The University of Texas MD Anderson Cancer Center
2016	Faculty Educator Award, The University of Texas MD Anderson Cancer Center
2016	Wayne B. Duddlesten Sr. Professorship in Honor of Dr. Ashish Kamat, Wayne Duddlesten Foundation
2013	Top Reviewer in Urology, American Urological Association (AUA)
2012	Outstanding Reviewer Award, The Journal of Urology
2012	Robert M. Chamberlain Distinguished Mentor Award (Nominee), The University of Texas MD Anderson Cancer Center
2011	Compassionate Doctor Award, Patient Recognition
2008	AUA Leadership Program Award, American Urological Association
2008	Best Doctors in America, Best In Medicine
2007	Clinical Research Committee Excellent Reviewer Award, The University of Texas MD Anderson Cancer Center
2005	Who's Who in America, 60th edition, Marquis Who's Who
2004	Faculty Award, American Association for Cancer Research (AACR)
2003	Bladder SPORE Developmental Research Program Award, National Cancer Institute (NCI)
2002	Scholar in Training Award, American Association for Cancer Research
2001	Outstanding Laparoendoscopist, Society of Laparoendoscopic Surgeons
2000	Best Published Papers in Urology, American Urological Association (AUA)
1999 - 2000	First Prize Presentation, American College of Surgeons
1999	First Prize Paper, West Virginia University
1999	Pfizer Scholar in Urology (National), Pfizer, Inc
1999	Second Prize Presentation, University of Pittsburgh
1997	Outstanding/Best Paper Presentation, West Virginia University
1992	Dr. L. H. Hiranandani Scholarship in Otorhinolaryngology, University of Bombay
1991	Gold Medal Performance, University of Bombay
1991	Shamdasani Foundation Scholarship for Standing First in University, University of Bombay
1991	Distinctions in Forensic Medicine and Medical Jurisprudence, Pharmacology, Microbiology, Biochemistry, and Preventive and Social Medicine, University of Bombay
1991	Manorama Vijayrat Hazarat Prize for Highest Cumulative Score, University of Bombay
1991	Seth Khimchand Amulakh Prize for Excellence in Pharmacology, University of Bombay

Professional Memberships

Sigma Xi Scientific Research Honor Society

2024 - Present

AUA Urology Scientific Mentoring and Research Training Academy

2020 - Present

Society for Immunotherapy of Cancer

2014 - Present

Texas Urological Society

2013 - Present

The Leo & Anne Albert Institute for Bladder Cancer Care & Research

2013 - Present

Society of Urologic Oncology

2011 - Present

International Young Urological Association

2011 - Present

International Bladder Cancer Group

2011 - Present

International Bladder Cancer Network

2010 - Present

American College of Surgeons

2005 - Present

Société Internationale d'Urologie

2005 - Present

American Society of Clinical Oncology

2004 - Present

American Association of Cancer Research

2003 - Present

South Central Section of the American Urological Association

2003 - Present

SWOG Cancer Research Network

2003 - Present

Harris County Medical Society

2001 - Present

Texas Medical Association

2001 - Present

American Medical Association

1999 - Present

American Urological Association

1999 - Present

Selected Publications

Peer-Reviewed Articles

Hariri D, Pavlick D, Spiess P, Li R, Kamat A, Grivas P, Agarwal N, Gupta S, Necchi A, Bratslavsky G, Basnet A, Jacob J, Ross J, Kravtsov O. Primary sarcomas of the bladder and prostate: A genomic landscape study. Pathol Res Pract 267:155840, 2025. e-Pub 2025. PMID: 39965403.
Annapureddy D, Taylor JI, Kamat AM, O'Donnell MA, Howard J, Tan WS, McElree IM, Davaro F, Yim K, Harrington S, Dyer E, Black AJ, Kanabur P, Roumiguie M, Lerner S, Black PC, Raman JD, Preston MA, Steinberg G, Huang W, Li R, Packiam VT, Woldu SL, Lotan Y. Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guerin Unresponsive Non-muscle-invasive Bladder Cancer Undergoing Bladder-sparing Therapies. Eur Urol Focus, 2025. e-Pub 2025. PMID: 39922753.
Lotan, Y, Krishna, V, Abuzeid, WM, Launer, B, Chang, SS, Krishna, V, Shingi, S, Gordetsky, JB, Gerald, T, Woldu, SL, Shkolyar, E, Hayne, D, Redfern, A, Spalding, L, Stewart, CA, Eyzaguirre, E, Imtiaz, S, Narayan, VM, Packiam, V, O'Donnell, M, Li, R, Baekelandt, L, Joniau, S, Zuiverloon, TC, Fernandez, M, Schultz, M, Hensley, PJ, Allison, D, Taylor, JA, Hamza, A, Kamat, A, Nimgaonkar, V, Sonawane, S, Miller, DL, Watson, D, Vrabac, D, Joshi, A, Shah, JB, Williams, SB. Predicting Response to Intravesical Bacillus Calmette-Guérin in High-Risk Nonmuscle-Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay. Journal of Urology 213(2):192-204, 2025. e-Pub 2025. PMID: 39383345.
Taylor, J, Kamat, A, O'Donnell, M, Annapureddy, D, Howard, JM, Tan, WS, McElree, IM, Davaro, F, Yim, K, Harrington, S, Dyer, E, Black, AJ, Kanabur, P, Roumiguie, M, Lerner, SP, Black, P, Raman, JD, Preston, MA, Steinberg, GD, Huang, WC, Li, R, Packiam, V, Woldu, SL, Lotan, Y. Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer. BJU international 135(2):260-268, 2025. e-Pub 2025. PMID: 39183466.
Moussa, MJ, Tabet, GC, Siefker-Radtke, AO, Xiao, L, Wilson, NR, Gao, J, Logothetis, CJ, Grivas, PD, Lee, B, Shah, AY, Msaouel, P, Li, R, Clemente, LC, Zhao, J, Tannir, NM, Kamat, A, Hansel, DE, Guo, CC, Campbell, M, Alhalabi, O. Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary Tract. Cancer medicine 14(2), 2025. e-Pub 2025. PMID: 39831734.
Carrero Longlax S, Koster KJ, Kamat AM, Lozano M, Lerner SP, Hannigan R, Nishiguchi T, Abhimanyu, Sheikh D, Ladki M, Portillo A, Koirala A, Patel TD, Spieler Z, Benjamin AB, Lebedev M, Ofili TU, Hutchison RW, Udeani G, Opperman LA, Neal G, Mandalakas AM, Netea MG, Arditi M, Avalos P, Grimm SL, Coarfa C, Cirillo JD, DiNardo AR. BCG-Induced DNA Methylation Changes Improve Coronavirus Disease 2019 Vaccine Immunity Without Decreasing the Risk for Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Open Forum Infect Dis 12(1):ofaf007, 2025. e-Pub 2025. PMID: 39872813.
Moussa MJ, Tabet GC, Siefker-Radtke AO, Xiao L, Wilson NR, Gao J, Logothetis CJ, Grivas P, Lee B, Shah AY, Msaouel P, Li R, Clemente LC, Zhao J, Tannir NM, Kamat AM, Hansel DE, Guo CC, Campbell MT, Alhalabi O. Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary Tract. Cancer Med 14(2):e70594, 2025. e-Pub 2025. PMID: 39831734.
Taylor J, Kamat AM, Annapureddy D, Khene ZE, Howard J, Tan WS, McElree IM, Facundo D, Yim K, Harrington S, Dyer E, Black AJ, Kanabur P, Roumiguie M, Lerner S, Black PC, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam VT, Woldu SL, Lotan Y, O'Donnell MA. Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guerin in Patients with Bacillus Calmette-Guerin-Unresponsive Non-Muscle Invasive Bladder Cancer. Eur Urol Oncol, 2024. e-Pub 2024. PMID: 39694798.
Carriere P, Alhalabi O, Gao J, Mohamad O, Campbell MT, Shah A, Goswami S, Bree K, Lee B, Navai N, Mok H, Mayo L, Guo C, Nguyen Q, McGuire S, Park R, Shah S, Hoffman K, Frank S, Tang C, Choi S, Kamat A, Hassanzadeh C. Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer. Clin Transl Radiat Oncol 49:100866, 2024. e-Pub 2024. PMID: 39403573.
Myers AA, Fang AM, Moussa MJ, Hwang H, Wilson NR, Campbell MT, Msaouel P, Lee BH, Guo CC, Zhang M, Zhao J, Siefker-Radtke AO, Kamat AM, Alhalabi O. Impact of systemic therapy on clinical T1 small-cell neuroendocrine carcinoma of the bladder. ESMO Open 9(11):103964, 2024. e-Pub 2024. PMID: 39471563.
Lobo N, Duan Z, Sood A, Zhao H, Lindskrog SV, Dyrskjot L, Giordano SH, Williams SB, Bree KK, Kamat AM. Sex Disparity in Non-muscle-invasive Bladder Cancer: Pitfalls of Large Population-based Data Sets and Lessons from an Integrated Analysis. Eur Urol Oncol, 2024. e-Pub 2024. PMID: 39448349.
Basin MF, Miguel CM, Jacob JM, Goldberg H, Grivas P, Spiess PE, Necchi A, Kamat AM, Pavlick DC, Huang RSP, Lin DI, Danziger N, Sokol ES, Sivakumar S, Graf R, Cheng L, Vasan N, Ross J, Basnet A, Bratslavsky G. Single-Hit and Multi-hit PIK3CA Short Variant Genomic Alterations in Clinically Advanced Prostate Cancer: A Genomic Landscape Study. Target Oncol, 2024. e-Pub 2024. PMID: 39369133.
Lerner SP, Tangen C, Svatek RS, Daneshmand S, Pohar KS, Skinner E, Schuckman A, Sagalowsky AI, Smith ND, Kamat AM, Kassouf W, Plets M, Bangs R, Koppie TM, Alva A, La Rosa FG, Pal SK, Kibel AS, Canter DJ, Thompson IM Jr. Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer. N Engl J Med 391(13):1206-1216, 2024. e-Pub 2024. PMID: 39589370.
Campbell MT, Shah AY, Msaouel P, Tannir NM, Siefker-Radtke AO, Kamat AM, Navai N, Dinney CPN, Rao P, Guo CC, Sheth RA, Venkatesan AM, Tidwell RS, Yadav SS, Gu A, Chen H, Macaluso M, Duan F, Basu S, Jindal S, Sharma P. A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer. Cancer Res Commun 4(9):2444-2453, 2024. e-Pub 2024. PMID: 39207194.
Taylor JI, Kamat AM, O'Donnell MA, Annapureddy D, Howard J, Tan WS, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black AJ, Kanabur P, Roumiguie M, Lerner S, Black PC, Raman JD, Preston MA, Steinberg G, Huang W, Li R, Packiam VT, Woldu SL, Lotan Y. Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer. BJU Int, 2024. e-Pub 2024. PMID: 39183466.
Brookman-May SD, Kamat AM, May M. Re: Achieving Benchmarks for National Quality Indicators Reduces Recurrence and Progression in Non-muscle-invasive Bladder Cancer. Eur Urol, 2024. e-Pub 2024. PMID: 39164169.
Tateo V, Cigliola A, Mercinelli C, Agarwal N, Grivas P, Kamat AM, Gibb EA, Moschini M, Brausi M, Dyrskjot L, Loriot Y, Gupta S, Colecchia M, Spiess PE, Ross JS, Necchi A. Optimizing the Use of Next-Generation Sequencing Assays in Patients With Urothelial Carcinoma: Recommendations by the 2023 San Raffaele Retreat Panel. Clin Genitourin Cancer 22(4):102091, 2024. e-Pub 2024. PMID: 38735133.
Cigliola A, Basnet A, Jacob JM, Mercinelli C, Tateo V, Patane DA, Bratslavsky G, Cheng L, Grivas P, Kamat AM, Spiess PE, Pavlick DC, Lin DI, Ross JS, Necchi A. Urachal and Nonurachal Adenocarcinomas of the Urinary Bladder: A Comprehensive Genomic Profiling Study. JCO Precis Oncol 8:e2400200, 2024. e-Pub 2024. PMID: 39151108.
Narayan VM, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Mashni J Jr, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Inman BA, Williams MB, Cookson MS, Chang SS, Sankin AI, O'Donnell MA, Sawutz D, Philipson R, Parker NR, Yla-Herttuala S, Rehm D, Jakobsen JS, Juul K, Dinney CPN. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guerin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol 212(1):74-86, 2024. e-Pub 2024. PMID: 38704840.
Soria F, Rosazza M, Livoti S, Moschini M, De Angelis M, Giudice FD, Pichler R, Hurle R, Mancon S, Carrion DM, Krajewski W, Mertens LS, D'Andrea D, Mari A, Di Maida F, Dutto D, Colucci F, Casale G, Fertitta G, Laukhtina E, Albisinni S, Pradere B, Teoh JYC, Shariat SF, Briganti A, Kamat AM, Gontero P. Clinical Validation of the Intermediate-risk Non-muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group Collaboration. Eur Urol Oncol, 2024. e-Pub 2024. PMID: 38906794.
Myers AA, Tan WS, Grajales V, Hwang H, Bree KK, Navai N, Lee BH, Dinney CPN, Kamat AM. Challenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Guerin Have an Effect?. Eur Urol, 2024. e-Pub 2024. PMID: 38879371.
Li R, Shah PH, Stewart TF, Nam JK, Bivalacqua TJ, Lamm DL, Uchio EM, Geynisman DM, Jacob JM, Meeks JJ, Dickstein R, Pearce SM, Kang SH, Jung SI, Kamat AM, Burke JM, Keegan KA, Steinberg GD. Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nat Med, 2024. e-Pub 2024. PMID: 38844794.
Hahn AW, Manyam GC, Chapin BF, Zhang M, Yu Y, Pettaway CA, Chery L, Pisters LL, Ward JF, Gregg JR, Papadopoulos J, Kamat AM, Lozano M, Hoang A, Broom B, Wang X, Huff CD, Logothetis CJ, Troncoso P, Pilie PG, Davis JW. A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates. BJU Int, 2024. e-Pub 2024. PMID: 38837608.
Necchi A, Roumiguie M, Kamat AM, Shore ND, Boormans JL, Esen AA, Lebret T, Kandori S, Bajorin DF, Krieger LEM, Niglio SA, Uchio EM, Seo HK, de Wit R, Singer EA, Grivas P, Nishiyama H, Li H, Baranwal P, Van den Sigtenhorst-Fijlstra M, Kapadia E, Kulkarni GS. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. Lancet Oncol 25(6):720-730, 2024. e-Pub 2024. PMID: 38740030.
Zheng L, Chen H, Zhao J, Roy-Chowdhuri S, Kamat AM, Alhalabi O, Gao J, Siefker-Radtke A, Hansel DE, Czerniak B, Guo CC. Plasmacytoid urothelial carcinoma of the urinary bladder-A clinicopathological and molecular analysis of 52 cases. Hum Pathol 148:1-6, 2024. e-Pub 2024. PMID: 38679207.
Contieri R, Tan WS, Grajales V, Hensley PJ, Martini A, Bree K, Myers A, Nogueras-Gonzalez G, Navai N, Dinney CP, Guo C, Kamat AM. Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy. BJU Int 133(6):733-741, 2024. e-Pub 2024. PMID: 38374533.
Liu K, Zhao H, Chen X, Nicoletti R, Vasdev N, Chiu PK, Ng CF, Kawada T, Laukhtina E, Mori K, Yanagisawa T, D'Andrea D, von Deimling M, Albisinni S, Krajewski W, Pradere B, Soria F, Moschini M, Enikeev D, Shariat S, Kamat A, Giannarini G, Teoh JY. A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Guerin Strains in Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol 7(3):438-446, 2024. e-Pub 2024. PMID: 37827948.
Tan WS, Ahmad A, Zhou Y, Nathan A, Ogunbo A, Gbolahan O, Kallam N, Smith R, Khalifeh M, Tan WP, Cohen D, Volanis D, Walter FM, Sasieni P, Kamat AM, Kelly JD. Hematuria Cancer Risk Score with Ultrasound Informs Cystoscopy Use in Patients with Hematuria. Eur Urol Oncol, 2024. e-Pub 2024. PMID: 38811250.
Leary JB, Enright T, Bakaloudi DR, Basnet A, Bratslavsky G, Jacob J, Spiess PE, Li R, Necchi A, Kamat AM, Pavlick DC, Danziger N, Huang RSP, Lin DI, Cheng L, Ross J, Talukder R, Grivas P. Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer. Target Oncol 19(3):447-458, 2024. e-Pub 2024. PMID: 38570422.
Gore, JL, Follmer, K, Reynolds, J, Nash, M, Anderson, CB, Catto, JW, Chamie, K, Daneshmand, S, Dickstein, RJ, Garg, T, Gilbert, SM, Guzzo, TJ, Kamat, A, Kates, M, Lane, BR, Lotan, Y, Mansour, AM, Master, VA, Montgomery, JS, Morris, D, Nepple, K, O'Neil, B, Patel, S, Pohar, KS, Porten, S, Riggs, SB, Sankin, A, Scarpato, KR, Shore, ND, Steinberg, GD, Strope, SA, Taylor, JM, Comstock, B, Kessler, LG, Wolff, EM, Smith, AB. Interruptions in bladder cancer care during the COVID-19 public health emergency. Urologic Oncology: Seminars and Original Investigations 42(4):116.e17-116.e21, 2024. e-Pub 2024. PMID: 38087711.
Posada JM, Yakirevich E, Kamat AM, Sood A, Jacob JM, Bratslavsky G, Grivas P, Spiess PE, Li R, Necchi A, Mega AE, Golijanin DJ, Pavlick D, Huang RSP, Lin D, Danziger N, Sokol ES, Sivakumar S, Ross JS, Cheng L. Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2. Mod Pathol 37(3):100424, 2024. e-Pub 2024. PMID: 38219954.
Myers AA, Kamat AM, Kilbert A, Galsky MD. Toward standardization in bladder cancer clinical trials: Guidance from the SITC-IBCG expert panel. J Immunother Cancer 12(2), 2024. e-Pub 2024. PMID: 38309724.
Sood A, Rudzinski JK, Labbate CV, Hensley PJ, Bree KK, Guo CC, Alhalabi O, Campbell MT, Siefker-Radtke AO, Navai N, Dinney CPN, Gao J, Kamat AM. Long-Term Oncological Outcomes in Patients Diagnosed With Nonmetastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience. J Urol 211(2):241-255, 2024. e-Pub 2024. PMID: 37922370.
Lobo N, Duan Z, Sood A, Tan WS, Grajales V, Contieri R, Lindskrog SV, Dyrskjot L, Zhao H, Giordano SH, Williams SB, Bree KK, Kamat AM. Association of Age with Non-muscle-invasive Bladder Cancer: Unearthing a Biological Basis for Epidemiological Disparities?. Eur Urol Oncol, 2024. e-Pub 2024. PMID: 38302322.
Warrick, JI, Al Ahmadie, H, Berman, DM, Black, P, Flaig, TW, Höglund, M, Bubendorf, L, Van Der Kwast, T, Cheng, L, Adeniran, A, Al-Ahimadie, H, Algaba, F, Allory, Y, Bhattarai, S, Black, P, Berman, DM, Bertz, S, Bubendorf, L, Carlsen, B, Carvalho, R, Cheng, L, Chijioke, O, Cho, YM, Comperat, EM, Di Cunha, I, Dagher, J, De Cunha, I, Delahunt, B, Downes, MR, Flaig, TW, Fleischmann, A, Florescu, C, Fontugne, J, Genitsch, V, Gløersen, GH, Von Gunten, M, Grobholz, R, Hanselarndt Hartmann, D, Hernandez, LH, Hogland, M, Huang, J, Jensen, B, Iczkowski, KA, Jimenez, R, Jovanovic, B, Kamat, A, Koellermann, J, Levin, T, Liedberg, F, Lopez-Beltran, A, Loya, AC, Lyngra, M, McHale, T, Mokeddem, K, Netto, G, Nourieh, M, O'Rourke, D, Ostahi, IA, Paner, GP, Picken, MM, Pineda, FG, Raspollini, CM, Reis, H, Ruoyu, S, Samaratunga, H, Semba, R, Shah, N, Shen, SS, Smith, SC, Smith, T, Srigley, JR, Suzigan, S, Swarbrick, N, Szalay, I, Talleraas, I, Tille, JC, Toma, M, Trias, I, Tsuzuki, T, Van Der Kwast, T, van Rhijn, B, Varma, M, Verbeke, SL, Verma, S, Vlajnic, T, Vlatkovic, L, Warren, AY, Warrick, J, Williamson, SR, Wobker, SE, Woods, C, Yang, C, Yoon, G. International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer. Working Group 4. American Journal of Surgical Pathology 48(1):E32-E42, 2024. e-Pub 2024. PMID: 37199442.
Kamat AM, Zheng X, Bos J, Cao M, Triantafyllou MS, Kottapalli AGP. Undulating Seal Whiskers Evolved Optimal Wavelength-to-Diameter Ratio for Efficient Reduction in Vortex-Induced Vibrations. Adv Sci (Weinh) 11(2):e2304304, 2024. e-Pub 2024. PMID: 37847914.
Grajales, V, Contieri, R, Tan, WS, Flores, M, Schultz, M, Pinochet, R, Bustamante, A, Kamat, A, Fernandez, M. Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer. Bladder Cancer 9(4):327-334, 2023. e-Pub 2023. PMID: 38994240.
Kamat, A, Apolo, AB, Babjuk, M, Bivalacqua, TJ, Black, P, Buckley, R, Campbell, M, Comperat, EM, Efstathiou, JA, Grivas, PD, Gupta, S, Kurtz, NJ, Lamm, DL, Lerner, SP, Li, R, McConkey, DJ, Redorta, JP, Powles, T, Psutka, SP, Shore, ND, Steinberg, GD, Sylvester, R, Witjes, JA, Galsky, MD. Definitions, End Points, and Clinical Trial Designs for Bladder Cancer. Journal of Clinical Oncology 41(35):5437-5447, 2023. e-Pub 2023. PMID: 37793077.
Ghelani, GH, Zerdan, MB, Jacob, J, Spiess, PE, Li, R, Necchi, A, Grivas, PD, Kamat, A, Danziger, N, Lin, D, Huang, RS, Decker, B, Sokol, E, Cheng, L, Pavlick, D, Ross, JS, Bratslavsky, G, Basnet, A. HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC). Urologic Oncology: Seminars and Original Investigations 41(12):486.e15-486.e23, 2023. e-Pub 2023. PMID: 37821306.
Contieri, R, Hensley, PJ, Tan, WS, Grajales, V, Bree, KK, Nogueras Gonzalez, G, Lee, B, Navai, N, Dinney, CP, Kamat, A. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. European Urology Oncology 6(6):590-596, 2023. e-Pub 2023. PMID: 37558542.
Alhalabi, O, Wilson, NR, Xiao, L, Lin, Y, Khandelwal, J, Moussa, MJ, Msaouel, P, Navai, N, Gao, J, Kamat, A, Pilie, PG, Shah, AY, Goswami, S, Matin, S, Kovitz, CA, Holla, V, Guo, C, Czerniak, BA, Logothetis, CJ, Corn, P, Dinney, CP, Campbell, M, Hansel, DE, Tannir, NM, Siefker-Radtke, AO. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. European Urology Oncology 6(6):611-620, 2023. e-Pub 2023. PMID: 37833193.
DiNardo, AR, Arditi, M, Kamat, A, Koster, KJ, Carrero, S, Nishiguchi, T, Lebedev, M, Benjamin, AB, Avalos, P, Lozano, M, Moule, MG, McCune, B, Herron, B, Ladki, M, Sheikh, D, Spears, M, Herrejon, IA, Dodge, C, Kumar, S, Hutchison, RW, Ofili, TU, Opperman, LA, Bernard, JA, Lerner, SP, Udeani, G, Neal, G, Netea, MG, Cirillo, JD. Bacillus Calmette-Guérin vaccination as defense against SARS-CoV-2 (BADAS). Trials 24(1), 2023. e-Pub 2023. PMID: 37794431.
Tan, WS, Contieri, R, Buffi, NM, Lughezzani, G, Grajales, V, Soloway, M, Casale, P, Hurle, R, Kamat, A. International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active Surveillance. Journal of Urology 210(5):763-770, 2023. e-Pub 2023. PMID: 37535836.
Tan WS, Contieri R, Buffi NM, Lughezzani G, Grajales V, Soloway M, Casale P, Hurle R, Kamat AM. Reply by Authors. J Urol 210(5):770, 2023. e-Pub 2023. PMID: 37622536.
Chang, E, Hahn, N, Lerner, SP, Fallah, J, Agrawal, S, Kamat, A, Bhatnagar, V, Svatek, RS, Jaigirdar, AA, Bross, P, Shore, ND, Kates, M, Sachse, K, Brewer, JR, O'Donnell, M, Steinberg, GD, Viviano, CJ, Bloomquist, E, Ribal, MJ, Galsky, MD, Oliver, R, Black, P, Al Ahmadie, H, Brothers, K, Pohar, KS, Dinney, CP, Feng, Z, Downs, TM, Porten, S, Smith, AB, Bangs, R, Psutka, SP, Agarwal, N, Amiri-Kordestani, L, Suzman, D, Pazdur, R, Kluetz, PG, Weinstock, C. Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer. Bladder Cancer 9(3):271-286, 2023. e-Pub 2023. PMID: 38993184.
Makaroff LE, Filicevas A, Boldon S, Hensley P, Black PC, Chisolm S, Demkiw S, Fernández MI, Sugimoto M, Jensen BT, Witjes WPJ, Bagshaw K, Cirefice-Funk L, Knight A, Kamat AM. Patient and Carer Experiences with Bladder Cancer: Results from a Global Survey in 45 Countries. Eur Urol 84(2):248-251, 2023. e-Pub 2023. PMID: 37236857.
Bree KK, Kokorovic A, Westerman ME, Hensley PJ, Brooks NA, Qiao W, Shen Y, Kamat AM, Dinney CP, Navai N. Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply. J Urol 210(2):101097JU0000000000003553, 2023. e-Pub 2023. PMID: 37211780.
Rose KM, Huelster HL, Meeks JJ, Faltas BM, Sonpavde GP, Lerner SP, Ross JS, Spiess PE, Grass GD, Jain RK, Kamat AM, Vosoughi A, Wang L, Wang X, Li R. Author Correction: Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease. Nat Rev Urol 20(7):452, 2023. e-Pub 2023. PMID: 37217696.
Tan WS, Grajales V, Contieri R, Hensley P, Bree K, Msaouel P, Guo CC, Nogueras-Gonzalez GM, Navai N, Dinney CP, Kamat AM. Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes. Eur Urol Open Sci 53:16-22, 2023. e-Pub 2023. PMID: 37441349.
Contieri R, Grajales V, Tan WS, Martini A, Sood A, Hensley P, Bree K, Lobo N, Nogueras-Gonzalez GM, Guo CC, Navai N, Dinney CP, Kamat AM. Impact of age >70?years on oncological outcomes in patients with NMIBC treated with BCG. BJU Int. e-Pub 2023. PMID: 37442564.
Tan WS, McElree IM, Davaro F, Steinberg RL, Bree K, Navai N, Dinney CP, O'Donnell MA, Li R, Kamat AM, Packiam VT. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. e-Pub 2023. PMID: 37468392.
Beijert IJ, Cheng L, Liedberg F, Plass K, Williamson SR, Gontero P, Ribal MJ, Babjuk M, Black PC, Kamat AM, Algaba F, Berman DM, Hartmann A, Masson-Lecomte A, Rouprêt M, Lopez-Beltran A, Samaratunga H, Shariat SF, Mostafid AH, Varma M, Shen S, Burger M, Tsuzuki T, Palou J, Compérat EM, Sylvester RJ, van der Kwast TH, van Rhijn BWG, Downes MR. International Opinions on Grading of Urothelial Carcinoma: A Survey Among European Association of Urology and International Society of Urological Pathology Members. Eur Urol Open Sci 52:154-165, 2023. e-Pub 2023. PMID: 37284047.
Tan WS, Hall E, Kamat AM, Kelly JD. Clinical trial design for non-muscle-invasive bladder cancer. Nat Rev Urol. e-Pub 2023. PMID: 37328547.
Paner GP, Kamat AM, Netto GJ, Samaratunga H, Varma M, Bubendorf L, van der Kwast TH, Cheng L, Consensus Panel MOTIBT. International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 2: Grading of Mixed Grade, Invasive Urothelial Carcinoma Including Histologic Subtypes and Divergent Differentiations, and Non-Urothelial Carcinomas. Am J Surg Pathol. e-Pub 2023. PMID: 37382156.
Tan WS, Tan MY, Alhalabi O, Campbell MT, Kamat AM, Gao J. Evolving systemic management of urothelial cancers. Curr Opin Oncol 35(3):186-199, 2023. e-Pub 2023. PMID: 36966497.
Tan WS, Grajales V, Bree K, Li R, Nogueras-Gonzalez GM, Navai N, Dinney C, Kamat AM. BCG unresponsive non-muscle invasive bladder cancer: Are the sub-groups equal?. BJU Int. e-Pub 2023. PMID: 37246493.
Necchi A, Joshi M, Bangs R, Makaroff L, Grivas P, Kamat AM, Kassouf W, Raggi D, Marandino L, Krupski T, Flaig TW, Spiess PE, Group (IBCG) GSORGT(ATIBC. Disparities in Access to Novel Systemic Therapies in Patients With Urinary Tract Cancer: Propagating Access, Policies and Resources Uniformly. Clin Genitourin Cancer 21(2):301-308, 2023. e-Pub 2023. PMID: 36344399.
Alhalabi O, Zhu Y, Hamza A, Qiao W, Lin Y, Wang RM, Shah AY, Campbell MT, Holla V, Kamat AM, Wang WL, Wang J, Chen J, Meng J, Zhang M, Bondaruk J, Titus M, Genovese G, Czerniak BA, Shaw KR, Meric-Bernstam F, Guo CC, Logothetis CJ, Siefker-Radtke A, Msaouel P, Wang L, Liu J, Gao J. Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol 6(2):228-232, 2023. e-Pub 2023. PMID: 34789422.
Hurle R, Soria F, Contieri R, Avolio PP, Mancon S, Lazzeri M, Bernasconi V, Mazzoli S, Pizzuto G, De Bellis M, Rosazza M, Livoti S, Lupia T, Corcione S, Lillaz B, De Rosa FG, Buffi NM, Kamat AM, Gontero P, Casale P. Evaluating the Protective Effect of Intravesical Bacillus Calmette-Guerin against SARS-CoV-2 in Non-Muscle Invasive Bladder Cancer Patients: A Multicenter Observational Trial. Cancers (Basel) 15(5), 2023. e-Pub 2023. PMID: 36900409.
Hensley PJ, Duan Z, Bree K, Sood A, Zhao H, Lobo N, Contieri R, Campbell MT, Guo CC, Navai N, Williams SB, Dinney CP, Kamat AM. Competing mortality risk from second primary malignancy in bladder cancer patients following radical cystectomy: Implications for survivorship. Urol Oncol 41(2):108.e11-108.e17, 2023. e-Pub 2023. PMID: 36404232.
Bree KK, Kokorovic A, Westerman ME, Hensley PJ, Brooks NA, Qiao W, Shen Y, Kamat AM, Dinney CP, Navai N. Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy is Prognostic but Not Therapeutic. J Urol 209(1):140-149, 2023. e-Pub 2023. PMID: 36250944.
Zheng X, Kamat AM, Cao M, Kottapalli AGP. Wavy Whiskers in Wakes: Explaining the Trail-Tracking Capabilities of Whisker Arrays on Seal Muzzles. Adv Sci (Weinh) 10(2):e2203062, 2023. e-Pub 2023. PMID: 36403235.
Chang E, Hahn NM, Lerner SP, Fallah J, Agrawal S, Kamat AM, Bhatnagar V, Svatek RS, Jaigirdar AA, Bross P, Shore N, Kates M, Sachse K, Brewer JR, O'Donnell MA, Steinberg GD, Viviano CJ, Bloomquist E, Ribal MJ, Galsky MD, Oliver R, Black PC, Al-Ahmadie H, Brothers K, Pohar K, Dinney CP, Feng Z, Downs TM, Porten SP, Smith AB, Bangs R, Psutka SP, Agarwal N, Amiri-Kordestani L, Suzman DL, Pazdur R, Kluetz PG, Weinstock C. Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer. Bladder Cancer 9(3):271-286, 2023. e-Pub 2023. PMID: 38993184.
Hensley PJ, Bree KK, Guo CC, Lobo N, Campbell MT, Pettaway CA, Kamat AM. Clinicopathological analysis and outcomes of inflammatory myofibroblastic tumours of the urinary bladder. BJU Int 130(5):604-610, 2022. e-Pub 2022. PMID: 34773684.
Westerman, ME, Bree, KK, Msaouel, P, Kukreja, JB, Mantaring, C, Rukundo, I, Gonzalez, MG, Gregg, JR, Casteel, KN, Matin, S, Lafleur, AD, Best, RN, Crump, LD, Cunningham, JM, Saucedo, MA, Valle, DD, Varghese, R, Adibi, M, Chapin, BF, Chery, LJ, Davis, JW, Dinney, CP, Graber, WJ, Kamat, A, Karam, JA, Navai, N, Papadopoulos, JN, Pettaway, CA, Pisters, LL, Smith III, T, Ward, JF, Westney, OL, Wood, CG. Apixaban vs Enoxaparin for Post-Surgical Extended-Duration Venous Thromboembolic Event Prophylaxis. Journal of Urology 208(4):886-895, 2022. e-Pub 2022. PMID: 36082549.
Comperat E, Amin MB, Cathomas R, Choudhury A, Santis MD, Kamat AM, Stenzl A, Thoeny HC, Witjes JA. Current best practice for bladder cancer: a narrative review of diagnostics and treatments. The Lancet, 2022. e-Pub 2022. PMID: 36174585.
Labbate CV, Hensley PJ, Miest TS, Qiao W, Adibi M, Shah AY, Chery L, Papadopoulos J, Siefker-Radtke AO, Gao J, Guo CC, Czerniak BA, Navai N, Kamat AM, Dinney CP, Campbell MT, Matin SF. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol. e-Pub 2022. PMID: 35961847.
Hensley PJ, Bree KK, Brooks N, Matulay J, Li R, Nogueras-Gonzalez GM, Nagaraju S, Navai N, Grossman HB, Dinney CP, Kamat AM. Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes. Eur Urol Oncol 5(3):347-356, 2022. e-Pub 2022. PMID: 33935020.
Golla V, Shan Y, Farran EJ, Stewart CA, Vu K, Yu A, Khaki AR, Parikh DA, Swanson TA, Keegan KA, Kamat AM, Tyler DS, Freedland SJ, Williams SB. Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer. Urol Oncol 40(6):273.e1-273.e9, 2022. e-Pub 2022. PMID: 35168881.
Bree KK, Hensley PJ, Lobo N, Brooks NA, Nogueras-Gonzalez GM, Guo CC, Navai N, Grossman HB, Dinney CP, Kamat AM. All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors. J Urol:101097JU0000000000002678. e-Pub 2022. PMID: 35770498.
Freudenburg E, Bagheri I, Srinivas S, Martinez A, Putluri N, Klaassen Z, Kamat AM, Konety BR, Kim WY, Dyrskjøt L, McConkey DJ, Freedland SJ, Black PC, Daneshmand S, Catto JWF, Williams SB. Race reporting and disparities regarding clinical trials in bladder cancer: a systematic review. Cancer Causes Control. e-Pub 2022. PMID: 35699798.
Pohar KS, Patel S, Lotan Y, Trabulsi E, Woods M, Downs T, Huang WC, Jones J, Taylor J, O'Donnell M, Bivalacqua TJ, DeCastro J, Steinberg G, Kamat AM, Resnick MJ, Konety B, Schoenberg M, Jones JS, Daneshmand S, Group Collaborators FBLS. Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study. Urol Oncol. e-Pub 2022. PMID: 35750559.
Freudenburg E, Shan Y, Martinez A, Srinivasan A, Movva G, Yu A, AlBayyaa M, Klaassen Z, Freedland SJ, Kamat AM, Williams SB. Geographic distribution of racial differences in mortality in muscle-invasive bladder cancer patients: an opportunity for improvement. Cancer Causes Control 33(4):613-622, 2022. e-Pub 2022. PMID: 35050417.
Adibi M, McCormick B, Economides MP, Petros F, Xiao L, Guo C, Shah A, Kamat AM, Dinney C, Navai N, Gao J, Siefker-Radtke A, Matin SF, Campbell MT. Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. Clin Genitourin Cancer 20(2):176-182, 2022. e-Pub 2022. PMID: 35039231.
Lobo N, Martini A, Kamat AM. Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther 22(4):1-10, 2022. e-Pub 2022. PMID: 35212590.
Zaleski MP, Chen H, Roy-Chowdhuri S, Patel KP, Luthra R, Routbort MJ, Kamat AM, Gao J, Siefker-Radtke A, Czerniak B, Guo CC. Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma. Am J Clin Pathol. e-Pub 2022. PMID: 35467000.
Mitra AP, Narayan VM, Mokkapati S, Miest T, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown GA, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL, Sankin AI, Boyd A, O'Donnell MA, Philipson R, Ylä-Herttuala S, Sawutz D, Parker NR, McConkey DJ, Dinney CPN. Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol 81(3):223-228, 2022. e-Pub 2022. PMID: 34933753.
Hensley PJ, Kamat AM. Re: Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol 81(3):316-317, 2022. e-Pub 2022. PMID: 35039182.
Bree KK, Shan Y, Hensley PJ, Lobo N, Hu C, Tyler DS, Chamie K, Kamat AM, Williams SB. Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non-Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013. JAMA Netw Open 5(3):e223050, 2022. e-Pub 2022. PMID: 35302627.
Khanna A, Miest T, Sharma V, Campbell R, Hensley P, Thapa P, Zganjar A, Tollefson MK, Thompson RH, Frank I, Karnes RJ, Murthy PB, Haber GP, Navai N, Kamat AM, Dinney C, Lee B, Boorjian SA. Role of Lymphadenectomy during Radical Cystectomy for Nonmuscle-Invasive Bladder Cancer: Results from a Multi-Institutional Experience. J Urol 207(3):551-558, 2022. e-Pub 2022. PMID: 34694143.
Lobo N, Hensley PJ, Bree KK, Nogueras-Gonzalez GM, Navai N, Dinney CP, Sylvester RJ, Kamat AM. Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin. Eur Urol Oncol 5(1):84-91, 2022. e-Pub 2022. PMID: 34920986.
Kamat, A, Lobo, N, Lerner, SP, Li, R, Matulay, JT, Palou, J, Witjes, JA, Rouprêt, M, Smith, AB, Chang, SS, Shore, ND, Steinberg, GD, Dinney, CP, Svatek, RS, Lamm, DL. Reduced Dose Intravesical Bacillus Calmette-Guerin. Bladder Cancer 8(2):113-117, 2022. e-Pub 2022. PMID: 38993360.
Williams SB, Gavaghan MB, Fernandez A, Daneshmand S, Kamat AM. Macro and microeconomics of blue light cystoscopy with CYSVIEW® in non-muscle invasive bladder cancer. Urol Oncol 40(1):10.e7-10.e12, 2022. e-Pub 2022. PMID: 34158205.
Laukhtina E, Shim SR, Mori K, D'Andrea D, Soria F, Rajwa P, Mostafaei H, Compérat E, Cimadamore A, Moschini M, Teoh JY, Enikeev D, Xylinas E, Lotan Y, Palou J, Gontero P, Babjuk M, Witjes JA, Kamat AM, Roupret M, Shariat SF, Pradere B, Working Group EAOUAUEUC. Corrigendum to "Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis" [Eur Urol Oncol 2021;4:927-42]. Eur Urol Oncol. e-Pub 2022. PMID: 35063436.
Steinberg RL, Packiam VT, Thomas LJ, Brooks N, Vitale A, Mott SL, Crump T, Wang J, DeWolf WC, Lamm DL, Kates M, Hyndman ME, Kamat AM, Bivalacqua TJ, Nepple KG, O'Donnell MA. Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG. Urol Oncol 40(1):9.e1-9.e7, 2022. e-Pub 2022. PMID: 34092482.
Alhalabi O, Campbell MT, Xiao L, Adriazola AC, Wilson NR, Siefker-Radtke AO, Corn PG, Zurita A, Jonasch E, Gao J, Adibi M, Kamat AM, Navai N, Pisters LL, Dinney C, Matin SF, Shah AY. Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma. BJUI Compass 3(1):37-44, 2022. e-Pub 2022. PMID: 35475152.
Murakami K, Kamat AM, Dai Y, Pagano I, Chen R, Sun Y, Gupta A, Goodison S, Rosser CJ, Furuya H. Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot study. Cancer Biomark 33(1):151-157, 2022. e-Pub 2022. PMID: 34511488.
Hinestrosa JP, Kurzrock R, Lewis JM, Schork NJ, Schroeder G, Kamat AM, Lowy AM, Eskander RN, Perrera O, Searson D, Rastegar K, Hughes JR, Ortiz V, Clark I, Balcer HI, Arakelyan L, Turner R, Billings PR, Adler MJ, Lippman SM, Krishnan R. Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test. Commun Med (Lond) 2:29, 2022. e-Pub 2022. PMID: 35603292.
Leow JJ, Tan WS, Tan WP, Tan TW, Chan VW, Tikkinen KAO, Kamat AM, Sengupta S, Meng MV, Shariat S, Roupret M, Decaestecker K, Vasdev N, Chong YL, Enikeev D, Giannarini G, Ficarra V, Teoh JY, Collaborators U. A systematic review and meta-analysis on delaying surgery for urothelial carcinoma of bladder and upper tract urothelial carcinoma: Implications for the COVID19 pandemic and beyond. Front Surg 9:879774, 2022. e-Pub 2022. PMID: 36268209.
Brooks, NA, Puri, A, Garg, S, Nag, S, Corbo, J, Turabi, AE, Kaka, N, Zemmel, RW, Hegarty, PK, Kamat AM. The association of Coronavirus Disease-19 mortality and prior bacille Calmette-Guerin vaccination. Scientific reports 11(1), 2021. e-Pub 2021. PMID: 33436946.
Chan, VS, Tan, WS, Leow, JJ, Tan, WP, Ong, WK, Chiu, KP, Gurung, P, Pirola, GM, Orecchia, L, Liew, MC, Lee, HY, Wang, Y, Chen, IA, Castellani, D, Wroclawski, ML, Mayor, N, Sathianathen, NJ, Braga, I, Liu, Z, Moon, D, Tikkinen, K, Kamat AM, Meng, MV, Ficarra, V, Giannarini, G, Teoh, J. Delayed surgery for localised and metastatic renal cell carcinoma. World journal of urology 39(12):4295-4303, 2021. e-Pub 2021. PMID: 34031748.
Lobo N, Hensley PJ, Bree KK, Nogueras-Gonzalez GM, Navai N, Dinney CP, Kamat AM. Should Patients With Non-Muscle-Invasive Bladder Cancer Discontinue Fibrin Clot Inhibitors During BCG?. BJU Int. e-Pub 2021. PMID: 34854189.
Bree, KK, Hensley, PJ, Brooks, NA, Matulay, JT, Nogueras Gonzalez, G, Navai, N, Dinney, CP, Kamat, A. Impact of sex on response to BCG in non-muscle invasive bladder cancer patients. World journal of urology 39(11):4143-4149, 2021. e-Pub 2021. PMID: 34117914.
Lobo N, Bree KK, Hensley PJ, Nogueras-Gonzalez GM, Abraham P, Navai N, Dinney CP, Kamat AM. Reduced Dose BCG in an Era of BCG Shortage: Real-World Experience from a Tertiary Cancer Centre. BJU Int. e-Pub 2021. PMID: 34847263.
Laukhtina E, Shim SR, Mori K, D‘Andrea D, Soria F, Rajwa P, Mostafaei H, Comperat E, Cimadamore A, Moschini M, Teoh JY, Enikeev D, Xylinas E, Lotanm Y, Palou J, Gontero P, Babjuk M, J Alfred Witjes J, Kamat AM, Roupret M, Shariat SF, Pradere B, Working Group EAOUAU(UC. Accuracy of novel urinary biomarker tests for diagnosis and surveillance of NMIBC: A systematic review, diagnostic test accuracy and network meta-analyses. Eur Urol Oncol 33, Supplememt 3:S397-S398, 2021. e-Pub 2021.
Alhalabi O, Campbell MT, Xiao L, Adriazola AC, Wilson NR, Siefker-Radtke A, Corn PG, Zurita A, Jonasch E, Gao J, Adibi M, Kamat AM, Navai N, Pisters LL, Dinney C, Matin SF, Shah AY. Multimodal kidney‐preserving approach in localised and locally advanced high‐risk upper tract urothelial carcinoma. BJUI Compass. e-Pub 2021.
Bree KK, Hensley PJ, Westerman ME, Kokorovic A, Nogueras-Gonzalez GM, Dinney CP, Kamat AM, Navai N. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. J Urol 206(3):577-585, 2021. e-Pub 2021. PMID: 33872050.
Balar AV, Kamat AM, de Wit R, investigators K. Pembrolizumab monotherapy for high-risk, non-muscle invasive bladder cancer - Authors' reply. Lancet Oncol 22(9):e380, 2021. e-Pub 2021. PMID: 34478664.
Hensley PJ, Kamat AM. Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Implications for Clinical Trial Design. Reply. J Urol:101097JU0000000000002238. e-Pub 2021. PMID: 34520231.
Galsky MD, Balar AV, Black PC, Campbell MT, Dykstra GS, Grivas P, Gupta S, Hoimes CJ, Lopez LP, Meeks JJ, Plimack ER, Rosenberg JE, Shore N, Steinberg GD, Kamat AM. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. J Immunother Cancer 9(7), 2021. e-Pub 2021. PMID: 34266883.
Westerman ME, Bree KK, Kokorovic A, Frank J, Wang XS, Kamat AM, Dinney CPN, Navai N. What Women Want: Radical Cystectomy and Perioperative Sexual Function Educational Needs. Urology. e-Pub 2021. PMID: 34186127.
Hensley PJ, Bree KK, Campbell MT, Alhalabi O, Kokorovic A, Miest T, Nogueras-Gonzalez GM, Gao J, Siefker-Radtke AO, Guo CC, Navai N, Dinney CP, Kamat AM. Progression of Disease after BCG Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. J Urol:101097JU0000000000001943. e-Pub 2021. PMID: 34184926.
Giannarini G, Agarwal N, Apolo AB, Briganti A, Grivas P, Gupta S, Kamat AM, Montorsi F, Rouprêt M, Necchi A. Urologists, You'll Never Walk Alone! How Novel Immunotherapy and Modern Imaging May Change the Management of Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. e-Pub 2021. PMID: 34147473.
Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguié M, Krieger LEM, Singer EA, Bajorin DF, Grivas P, Seo HK, Nishiyama H, Konety BR, Li H, Nam K, Kapadia E, Frenkl T, de Wit R. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. e-Pub 2021. PMID: 34051177.
Hensley PJ, Bree KK, Brooks N, Matulay J, Li R, Nogueras González GM, Navai N, Grossman HB, Dinney CP, Kamat AM. Time Interval from Transurethral Resection of Bladder Tumor to BCG Induction Does Not Impact Therapeutic Response. BJU Int. e-Pub 2021. PMID: 33783950.
Vlahou A, Hallinan D, Apweiler R, Argiles A, Beige J, Benigni A, Bischoff R, Black PC, Boehm F, Céraline J, Chrousos GP, Delles C, Evenepoel P, Fridolin I, Glorieux G, van Gool AJ, Heidegger I, Ioannidis JPA, Jankowski J, Jankowski V, Jeronimo C, Kamat AM, Masereeuw R, Mayer G, Mischak H, Ortiz A, Remuzzi G, Rossing P, Schanstra JP, Schmitz-Dräger BJ, Spasovski G, Staessen JA, Stamatialis D, Stenvinkel P, Wanner C, Williams SB, Zannad F, Zoccali C, Vanholder R. Data Sharing Under the General Data Protection Regulation: Time to Harmonize Law and Research Ethics?. Hypertension:HYPERTENSIONAHA12016340. e-Pub 2021. PMID: 33583200.
Baack Kukreja J, Li R, Narayan VM, Lim A, Seif MA, Wang X, Kamat A, Dinney CP, Navai N. Oncologic equipoise between robotic and open radical cystectomy. J Endourol. e-Pub 2021. PMID: 33619985.
Boorjian, SA, Alemozaffar, M, Konety, B, Shore, ND, Gomella, L, Kamat, A, Bivalacqua, TJ, Montgomery, JS, Lerner, SP, Busby, JE, Poch, M, Crispen, PL, Steinberg, GD, Schuckman, AK, Downs, TM, Svatek, RS, Mashni, J, Lane, BR, Guzzo, TJ, Bratslavsky, G, Karsh, L, Woods, M, Brown, G, Canter, DJ, Luchey, A, Lotan, Y, Krupski, TL, Inman, BA, Williams, MB, Cookson, MS, Keegan, KA, Andriole, GL, Sankin, A, Boyd, A, O'Donnell, M, Sawutz, DG, Philipson, R, Coll, R, Narayan, VM, Treasure, FP, Ylä-Herttuala, S, Parker, NR, Dinney, CP. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer. The lancet oncology 22(1):107-117, 2021. e-Pub 2021. PMID: 33253641.
Jazzar U, Bergerot CD, Shan Y, Wallis CJ, Freedland SJ, Kamat AM, Tyler DS, Baillargeon J, Kuo YF, Klaassen Z, Williams SB. Use of Psychotropic Drugs Among Older Patients with Bladder Cancer in the United States. Psychooncology. e-Pub 2021. PMID: 33507622.
Matulay JT, Li R, Hensley PJ, Brooks NA, Narayan VM, Grossman HB, Navai N, Dinney CPN, Kamat AM. Contemporary Outcomes of Patients with Non-Muscle Invasive Bladder Cancer Treated with BCG Therapy: Implications for Clinical Trial Design. J Urol:101097JU0000000000001633. e-Pub 2021. PMID: 33502236.
Bree KK, Hensley PJ, Brooks NA, Matulay J, Li R, Nogueras Gonzalez GM, Navai N, Grossman HB, Matin SF, Dinney CP, Kamat AM. Impact of upper tract urothelial carcinoma on response to bcg in patients with non-muscle invasive bladder cancer. BJU Int. e-Pub 2021. PMID: 33484074.
Yang M, Georgieva MV, Bocharova I, Vembusubramanian M, Qian K, Guo A, Kamat AM. The Impact of Progression on Healthcare Resource Utilization and Costs Among Patients with High-Grade Non-Muscle Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy: A Retrospective SEER-Medicare Analysis. Adv Ther. e-Pub 2021. PMID: 33543424.
Kukreja JB, Seif MA, Mery MW, Incalcaterra JR, Kamat AM, Dinney CP, Shah JB, Feeley TW, Navai N. Utilizing time-driven activity-based costing to determine open radical cystectomy and ileal conduit surgical episode cost drivers. Urol Oncol. e-Pub 2020. PMID: 33308972.
Brooks NA, Kokorovic A, Xiao L, Matulay JT, Li R, Ranasinghe WKB, Nagaraju S, Shen Y, Gao J, Navai N, Dinney CPN, Grossman HB, Kamat AM. The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin. BJU Int. e-Pub 2020. PMID: 33210440.
Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. e-Pub 2020. PMID: 33046869.
Li R, Sundi D, Zhang J, Kim Y, Sylvester RJ, Spiess PE, Poch MA, Sexton WJ, Black PC, McKiernan JM, Steinberg GD, Kamat AM, Gilbert SM. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin. Eur Urol 78(3):387-399, 2020. e-Pub 2020. PMID: 32143924.
Bagheri I, Shan Y, Klaassen Z, Kamat AM, Konety B, Mehta HB, Baillargeon JG, Srinivas S, Tyler DS, Swanson TA, Kaul S, Hollenbeck BK, Williams SB. Comparing Costs of Radical Versus Partial Cystectomy for Patients Diagnosed With Localized Muscle-Invasive Bladder Cancer: Understanding the Value of Surgical Care. Urology. e-Pub 2020. PMID: 32980405.
Teoh JY, Huang J, Ko WY, Lok V, Choi P, Ng CF, Sengupta S, Mostafid H, Kamat AM, Black PC, Shariat S, Babjuk M, Wong MC. Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. Eur Urol. e-Pub 2020. PMID: 32972792.
Necchi A, Gallina A, Dyrskjøt L, Roupret M, Kamat AM, Spiess PE, Grivas P, Gibb EA, Briganti A, Montorsi F. Converging Roads to Early Bladder Cancer. Eur Urol 78(2):127-130, 2020. e-Pub 2020. PMID: 32197887.
Li R, Gilbert SM, Kamat AM. Unraveling the Mechanism of the Antitumor Activity of Bacillus Calmette-Guérin. Eur Urol. e-Pub 2020. PMID: 32861573.
Golla, V, Shan, Y, Mehta, HB, Klaassen, Z, Tyler, DS, Baillargeon, J, Kamat, A, Freedland, S, Gore, JL, Chamie, K, Kuo, YF, Williams, SB. Impact of Diagnosing Urologists and Hospitals on the Use of Radical Cystectomy. European Urology Open Science 19:27-36, 2020. e-Pub 2020. PMID: 34337452.
Hwang MJ, Kamat AM, Dinney CP, Czerniak B, Guo CC. Bladder Cancer Involving Smooth Muscle of Indeterminate Type or Muscularis Mucosae in Transurethral Biopsy Specimens. Am J Clin Pathol 154(2):208-214, 2020. e-Pub 2020. PMID: 32253420.
Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Van Der Kwast T, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, De Visschere PJL, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, Oyen WJG, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Willemse PM, Williams A, Zigeuner R, Horwich A. Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]. Eur Urol 78(1):e48-e50, 2020. e-Pub 2020. PMID: 32446863.
O'Connor E, Teh J, Kamat AM, Lawrentschuk N. Bacillus Calmette Guérin (BCG) vaccination use in the fight against COVID-19 - what's old is new again?. Future Oncol 16(19):1323-1325, 2020. e-Pub 2020. PMID: 32406253.
Westerman ME, Kokorovic A, Wang XS, Lim A, Garcia-Gonzalez A, Seif M, Wang R, Kamat AM, Dinney CPN, Navai N. Radical Cystectomy and Perioperative Sexual Function: A Cross-Sectional Analysis. J Sex Med. e-Pub 2020. PMID: 32713807.
Yang, G, Bondaruk, J, Cogdell, D, Wang, Z, Lee, S, Lee, JG, Zhang, S, Choi, W, Wang, Y, Liang, Y, Wang, G, Wang, Y, Yao, H, Dadhania, V, Gao, J, Logothetis, CJ, Siefker-Radtke, AO, Kamat, A, Dinney, CP, Theodorescu, D, Kimmel, M, Wei, P, Guo, CC, Weinstein, JN, McConkey, DJ, Czerniak, BA. Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. iScience 23(6), 2020. e-Pub 2020. PMID: 32521509.
Mostafid H, Babjuk M, Bochner B, Lerner SP, Witjes F, Palou J, Roupret M, Shariat S, Gontero P, van Rhijn B, Zigeuner R, Sylvester R, Comperat E, Burger M, Malavaud B, Soloway M, Williams S, Black P, Daneshmand S, Steinberg G, Brausi M, Catto J, Kamat AM. Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. Eur Urol 77(6):669-670, 2020. e-Pub 2020. PMID: 32192815.
Steinberg RL, Thomas LJ, Brooks N, Mott SL, Vitale A, Crump T, Rao MY, Daniels MJ, Wang J, Nagaraju S, DeWolf WC, Lamm DL, Kates M, Hyndman ME, Kamat AM, Bivalacqua TJ, Nepple KG, O'Donnell MA. Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy of Non-muscle Invasive Bladder Cancer. J Urol 203(5):101097JU0000000000000688, 2020. e-Pub 2020. PMID: 31821066.
Matulay JT, Tabayoyong W, Duplisea JJ, Chang C, Daneshmand S, Gore JL, Holzbeierlein JM, Karsh LI, Kim SP, Konety BR, Li R, McKiernan JM, Messing EM, Steinberg GD, Williams SB, Kamat AM. Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members. Urol Oncol. e-Pub 2020. PMID: 32430255.
Brooks N, Nagaraju S, Matulay J, Han XY, Kamat AM. Bacillus Calmette-Guérin Retains Clinically Relevant Viability for up to 72 Hours After Reconstitution: Potential Implications for Clinical Practice in Times of Shortage. Eur Urol Oncol. e-Pub 2020. PMID: 32475716.
Kamat AM, Gontero P, Palou J. How Should I Manage a Patient with Tumor Recurrence Despite Adequate Bacille Calmette-Guérin?. Eur Urol Oncol 3(2):252-257, 2020. e-Pub 2020. PMID: 31307960.
Williams SB, Black PC, Dyrskjøt L, Seiler R, Schmitz-Dräger B, Nawroth R, Todenhöfer T, Kamat AM, Goebell PJ. Re: Aurélie Kamoun, Aurélien de Reyniès, Yves Allory, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.09.006: A Statement from the International Bladder Cancer Network. Eur Urol 77(4):e105-e106, 2020. e-Pub 2020. PMID: 31787429.
Kamat AM, Shore N, Hahn N, Alanee S, Nishiyama H, Shariat S, Nam K, Kapadia E, Frenkl T, Steinberg G. KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC. Future Oncol 16(10):507-516, 2020. e-Pub 2020. PMID: 32162533.
Hegarty PK, Sfakianos JP, Giannarini G, DiNardo AR, Kamat AM. COVID-19 and Bacillus Calmette-Guérin: What is the Link?. Eur Urol Oncol, 2020. e-Pub 2020. PMID: 32327396.
Jazzar U, Shan Y, Klaassen Z, Freedland SJ, Kamat AM, Raji MA, Masel T, Tyler DS, Baillargeon J, Kuo YF, Mehta HB, Bergerot CD, Williams SB. Impact of Alzheimer's disease and related dementia diagnosis following treatment for bladder cancer. J Geriatr Oncol, 2020. e-Pub 2020. PMID: 32354675.
Narayan VM, Seif MA, Lim AH, Li R, Matulay JT, Kukreja JB, Qiao W, Hwang H, Shah JB, Pisters L, Kamat AM, Dinney C, Navai N. Radical cystectomy in women: Impact of the robot-assisted versus open approach on surgical outcomes. Urol Oncol 38(4):247-254, 2020. e-Pub 2020. PMID: 31953001.
EIML L, Oddens JR, Vernooij RWM, Li R, Kamat A, Dinney CP, Mengual L, Alcaraz A, Izquierdo L, Savic S, Thalmann GN, Bubendorf L, Sylvester RJ, de Reijke TM. The Role of Fluorescence in Situ Hybridization for Predicting Recurrence after Adjuvant Bacillus Calmette-Guérin in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer Patients: A Systematic Review and Meta-Analysis of Individual Patient Data. J Urol 203(2):101097JU0000000000000566, 2020. e-Pub 2020. PMID: 31549936.
Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees. Eur Urol 77(2):223-250, 2020. e-Pub 2020. PMID: 31753752.
Kates M, Matoso A, Choi W, Baras AS, Daniels MJ, Lombardo K, Brant A, Mikkilineni N, McConkey DJ, Kamat AM, Svatek RS, Porten SP, Meeks JJ, Lerner SP, Dinney CP, Black PC, McKiernan JM, Anderson C, Drake CG, Bivalacqua TJ. Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG Unresponsive Trials. Clin Cancer Res 26(4):882-891, 2020. e-Pub 2020. PMID: 31712383.
Apolo AB, Milowsky MI, Kim L, Inman BA, Kamat AM, Steinberg G, Bagheri M, Krishnasamy VP, Marko J, Dinney CP, Bangs R, Sweis RF, Maher VE, Ibrahim A, Liu K, Werntz R, Cross F, Beaver JA, Singh H, Pazdur R, Blumenthal GM, Lerner SP, Bajorin DF, Rosenberg JE, Agrawal S. Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. JAMA Oncol:1-9. e-Pub 2019. PMID: 31670753.
Burger M, Kamat AM, McConkey D. Does Variant Histology Change Management of Non-muscle-invasive Bladder Cancer?. Eur Urol Oncol. e-Pub 2019. PMID: 31395481.

Invited Articles

Ferguson JE, Kamat AM. It's all about the perspective: Removing bias when co-managing patients with high-grade T1 bladder cancer and localized prostate cancer-A competing risks analysis. Urol Oncol. e-Pub 2017. PMID: 29158136.
Porten SP, Willis D, Kamat AM. Variant histology: role in management and prognosis of nonmuscle invasive bladder cancer. Curr Opin Urol. e-Pub 2014. PMID: 24921905.
Jinesh GG, Willis DL, Kamat AM. Bladder Cancer Stem Cells: Biological and Therapeutic Perspectives. Curr Stem Cell Res Ther. e-Pub 2013. PMID: 24236543.

Editorials

Kamat AM, Frankel P. Rethinking the Path to Bladder Cancer Staging: Can Magnetic Resonance Imaging Speed Up Time to Receipt of Therapy in Patients With Muscle-Invasive Bladder Cancer?. J Clin Oncol:JCO2402482, 2025. PMID: 39908478.
Bochner BH, Kamat AM, Bivalacqua TJ. Open vs Robotic Cystectomy: Case Closed?. J Urol 211(3):473-475, 2024. PMID: 38109705.
Myers AA, Kamat AM. Statins and BCG response: Is there more to the story?. Scott Med J 69(1):1-2, 2024. PMID: 38557231.
Hensley, PJ, Choudhury, A, Khaki, AR, Grivas, PD, Kamat, A. The 2023 European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer. European urology 85(1):32-34, 2024. PMID: 37919189.
Basile G, Pradere B, Bellmunt J, Roupret M, Kamat AM, Seisen T. A Plea for the Use of Video-recorded Cystoscopy for Blinded Independent Central Review of Tumor Response in Open-label Non-muscle invasive Bladder Cancer Trials. Eur Urol Oncol 6(5):453-455, 2023. PMID: 37604762.
van der Kwast T, Van Rhijn B, Kamat AM Cheng L. Reply to Rodolfo Montironi, Marina Scarpelli, Alessia Cimadamore, and Gregor Mikuz's Letter to the Editor re: Theo van der Kwast, Fredrik Liedberg, Peter C. Black, et al. International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2021.03.017. Focus on Our Personal Recollections and Observations. Eur Urol Focus 8(3):885-886, 2022. PMID: 33992577.
Hensley PJ, Bree KK, Campbell MT, Alhalabi O, Kokorovic A, Miest T, Nogueras-Gonzalez GM, Gao J, Siefker-Radtke AO, Guo CC, Navai N, Dinney CP, Kamat AM. Reply by Authors. J Urol:101097JU000000000000194302. PMID: 34372685.
Li, R, Lerner, SP, Kamat, A. The Who, What, When, Where, and Why of Bacillus Calmette-Guérin-unresponsive Bladder Cancer. European urology 79(4):437-439, 2021. PMID: 33454163.
Matulay JT, Li R, Hensley PJ, Brooks NA, Narayan VM, Grossman HB, Navai N, Dinney CPN, Kamat AM. Reply by Authors. J Urol 205(6):pp 1620-1621. PMID: 33734859.
Kamat, A. Bladder Cancer Guidelines. European urology 79(1):105-106, 2021. PMID: 32360051.
Moschini, M, Shariat, SF, Black, P, Kamat, A, Stabile, A, Cathelineau, X, Kassouf, W, Bochner, BH, Xylinas, E, Rouprêt, M, Boorjian, SA, Catto, J, Sanchez-Salas, R. Do Not Learn a Technique, Learn the Biology Underlying the Disease. European urology 77(1):1-2, 2020. PMID: 31506227.
Black PC, Goebell PJ, Kamat AM, Nawroth R, Seiler R, Williams SB, Schmitz-Dräger BJ. Editorial: Basic research in bladder cancer - refining the tools. 3rd IBCN seminars series1. Urol Oncol. PMID: 30683454.
Black PC, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dräger BJ. Editorial: Managing locally advanced bladder cancer. Third International Bladder Cancer Network seminars series. Urol Oncol. PMID: 29548621.
Williams SB, Kamat AM. Optimal Management of Non-Muscle Invasive Micropapillary Variant Urothelial Carcinoma: Possibility For Missed Chance at Cure?. BJU Int. PMID: 26917454.
Williams SB, Kamat AM, Lamm DL. Pelvic Recurrence Following Radical Cystectomy: A Call to Arms. BJU Int. PMID: 25307493.
Kamat AM, Porten S. Myths and Mysteries Surrounding Bacillus Calmette-Guérin Therapy for Bladder Cancer. Eur Urol. PMID: 24199712.

Abstracts

Myers AA, Steinmetz AR, Grajales V, Bree KK, Duan Z, Makaraoff L, Kamat AM. MP70-16: Females with Bladder Cancer are Underrepresented in Clinical Trials in the United States. American Urological Association (AUA) Annual Meeting 2024 211(5S):e1135, 2024.
Myers AA, Fang AM, Moussa MJ, Wilson N, Campbell MT, Guo CC, Zhang M, Siefker-Radtke A, Kamat AM, Alhalabi O. MP53-09: Impact of Systemic Therapy in Clinical T1 Small-cell Neuroendocrine Carcinoma of the Bladder. American Urological Association (AUA) Annual Meeting 2024 211(5S):e866, 2024.
Grajales V, Duan Z, Tan WS, Contieri R, Myers A, Zhao H, Giordano S, Williams SB, Kamat AM. MP24-20: Impact of Mental Health Illness on Adherence to Surveillance and Treatment Guidelines in Non-Muscle Invasive Bladder Cancer Patients. American Urological Association (AUA) Annual Meeting 2024 211(5S):e401, 2024.
Grajales V, Contieri R, Tan WS, Tuke DG, Akhverdiyeva L, Hwang H, Myers A, Kamat AM. MP35-06: Picture Perfect Diagnoses: Evaluating Urologists' Tumor Identification Skills. American Urological Association (AUA) Annual Meeting 2024 211(5S):e582, 2024.
Myers AA, Tan WS, Grajales V, Hwang H, Bree KK, Navai N, Lee BH, N Dinney CP, Kamat AM. PD30-08: Elucidating the Response Rates to Continued Bacillus Calmette-Guerin (BCG) in patients with BCG Exposed Bladder Cancer. American Urological Association (AUA) Annual Meeting 2024 211(5S):e627, 2024.
Tan WS, Contieri R, Buffi N, Lughezzani G, Grajales V, Soloway M, Casale P, Hurle R, Kamat A. MP16-06: The International Bladder Cancer Group Intermediate-risk Non-muscle Invasive Bladder Cancer (IBCG IR-NMIBC) scoring system predicts the need for intervention for patients on active surveillance. American Urological Association (AUA Annual Meeting 2024) 211(5S):e241, 2024.
Myers AA, Tan WS, Grajales V, Hwang H, Bree KK, Navai N, Lee BH, Dinney CPN, Kamat AM. MP16-08: Challenging the Paradigm of "BCG Unresponsive" Bladder Cancer. American Urological Association (AUA) Annual Meeting 2024 211(5S):e242, 2024.
Tan WS, Grajales V, Contieri R, Hensley P, Bree K, Msaouel P, Guo C, Navai N, Dinney C, Kamat AM. PD13-12: Bladder sparing treatment in patients with BCG unresponsive non-muscle invasive bladder cancer: An analysis of long-term survival outcomes. The Journal of Urology 209(4):e410, 2023. e-Pub 2023.
Grajales V, Duan Z, Tan WS, Contieri R, Zhao H, Giordano S, Williams SB, Kamat AM. MP54-14: Mental health illness in patients with Non-Muscle Invasive Bladder Cancer. Does BCG play a role?. The Journal of Urology 209(4):e759, 2023. e-Pub 2023.
Tan WS, Ahmad A, Nathan A, Ogunbo A, Gbolahan O, Kallam N, Tan WP, Cohen D, Volanis D, Kamat AM, Kelly J. PD29-01: The Hematuria Cancer Risk Score: A validation study demonstrating reduction in the number needed to investigate while preserving fidelity of cancer detection. The Journal of Urology 209(4):e824, 2023. e-Pub 2023.
Lim A, Sood A, Narayan V, Seif M, Matulay J, Bree K, Campbell M, Kamat AM, Dinney C, Navai N. MP56-06: Pathologic Downstaging Rate and Predictive Biomarker Exploration in Patients with Biopsy-Proven Clinically Node Positive Bladder Cancer Undergoing Chemotherapy Followed by Radical Cystectomy. The Journal of Urology 209(4):e775, 2023. e-Pub 2023.
Lobo N, Sood A, Duan Z, Tan WS, Grajales V, Lindskrog SV, Dyrskjot L, Denmark A, Zhao H, Giordano S, Williams SB, Kamat AM. PD29-05: Association of Age With Non-Muscle Invasive Bladder Cancer: A Biological Basis For Epidemiological Disparities?. The Journal of Urology 209(4):e826, 2023. e-Pub 2023.
Kulkarni G, Richards K, Black PC, Rendon R, Chin J, Shore N, Jayram G, Kramolowsky E, Saltzstein D, Agarwal P, Belkoff L, O'Donnell M, Kamat AM, Zlotta A, Jewett MAS, Lamm D, DeGruttola V, Mandel A, Dumoulin-White RJ, Kassouf W. MP63-01: An Interim Analysis of a Phase II Clinical Study of Intravesical Photo Dynamic Therapy in Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Carcinoma In- Situ (CIS). The Journal of Urology 209(4):e871, 2023. e-Pub 2023.
Kulkarni GS, Kamat AM, Uchio EM, Roumiguie M, Krieger LEM, Bajorin DF, Grivas P, Seo HK, Nishiyama H, Konety BR, de Wit R, Kapadia E, Xing A, MVdS F, Boormans JL. MP63-05: Outcomes in Patients (Pts) With Bacillus Calmette-Guerin (BCG)-Unresponsive High-Risk (HR) Non-Muscle-Invasive Bladder Cancer (NMIBC) Who Underwent Radical Cystectomy (RC) Following Pembrolizumab (Pembro) Treatment in KEYNOTE-057 Cohort A. The Journal of Urology 209(4):e872, 2023. e-Pub 2023.
Contieri R, Hensley P, Tan WS, Grajales V, Bree K, Guo CC, Nogueras-Gonzalez GM, Navai N, Dinney CP, Kamat AM. MP63-06: Bacillus Calmette-Guerin vs Immediate Radical Cystectomy in EAU De. AUA Journals, 2023. e-Pub 2023.
Contieri R, Grajales V, Tan WS, Bree K, Hensley P, Guo CC, Nogueras-Gonzalez GM, Navai N, Dinney CP, Kamat AM. MP63-11: Advanced Age (>70 Years) Does not A‰ect Oncological Outcomes in Non-Muscle Invasive Bladder Cancer Patients Treated with Adequate Bacillus Calmette-Guerin: A Competing Risk Analysis from a Tertiary Care Center. The Journal of Urology 209(4), 2023. e-Pub 2023.
Contieri R, Tan WS, Grajales V, Bree K, Hensley P, Guo CC, Navai N, Dinney CP, Kamat AM. MP63-15: T1 Sub-staging is Associated with Worse Oncological Outcomes For Patients Treated with Bacillus Calmette-Guerin or Immediate Radical Cystectomy. The Journal of Urology 209(4):e877, 2023. e-Pub 2023.
Contieri R, Grajales V, Tan WS, Bree K, Hensley P, Guo CC, Nogueras-Gonzalez GM, Navai N, Dinney CP, Kamat AM. MP63-11: Advanced Age (>70 Years) Does not A‰ect Oncological Outcomes in Non-Muscle Invasive Bladder Cancer Patients Treated with Adequate Bacillus Calmette-Guerin: A Competing Risk Analysis from a Tertiary Care Center. The Journal of Urology 209(4), 2023. e-Pub 2023.
Kamat AM, Steinberg GD, Inman BA, Kates MR, Uchio EM, Porten SP, Roupret M, Redorta J, Catto JWF, Kulkarni GS, Powles T, Tyson M, Haas GP, Yu Y, Birrenkott M, Lotan Y. Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC)—Trial in progress. 2023 ASCO Genitourinary Cancers Symposium, 2023. e-Pub 2023.
Kulkarni GS, Richards KA, Black PC, Rendon RA, Chin J, Shore ND, Jayram G, Kramolowsky EV, Saltzstein D, Agarwal PK, Belkoff L, O'Donnell MA, Kamat AM, Jewett MAS, Lamm DL, DeGruttola V, Mandel A, Dumoulin-White R, Kassouf W. A phase II clinical study of intravesical photo dynamic therapy in patients with BCG-unresponsive NMIBC (interim analysis). 2023 ASCO Genitourinary Cancers Symposium, 2023. e-Pub 2023.
Necchi A, Roumiguié M, Esen AA, Lebret T, De Wit R, ND Shore ND, Bajorin DF, Krieger LEM, Kandori S, Uchio EM, Seo HK, Boormans J, Kamat AM, Singer EA, Grivas P, Nishiyama H, Nam K, Kapadia E, Van den Sigtenhorst-Fijlstra M, Kulkarni GS. Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette–Guérin (BCG): Results from cohort B of the phase 2 KEYNOTE-057 trial. 2023 ASCO Genitourinary Cancers Symposium, 2023. e-Pub 2023.
Necchi A, Roumiguié M, Esen AA, Lebret T, De Wit R, ND Shore ND, Bajorin DF, Krieger LEM, Kandori S, Uchio EM, Seo HK, Boormans J, Kamat AM, Singer EA, Grivas P, Nishiyama H, Nam K, Kapadia E, Van den Sigtenhorst-Fijlstra M, Kulkarni GS. LBA03-08: Pembrolizumab (pembro) for Patients (pts) With High-Risk Non-Muscle-Invasive Bladder Cancer (HR NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG): E‹cacy and Evaluation of Subsequent Cystectomy From Cohort B of the Phase 2 KEYNOTE-057 Study. Journal of Clinical Oncology 41(6), 2023. e-Pub 2023.
Sood A, Rudzinski JK, Labbate, CV, Hensley PJ, Bree KK, Guo CC, Alhalabi O, Campbell MT, Siefker-Radtke AO, Navai N, Dinney CPN, Gao JJ, Kamat AM. Long-Term Oncological Outcomes in Patients Diagnosed with Non-Metastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience. 23rd Annual Meeting of the Society of Urologic Oncology (SUO), 2022. e-Pub 2022.
Kulkarni GS, Kamat AM, Uchio EM, Roumiguie M, Krieger LEM, Singer EA, Bajorin DF, Grivas P, Seo HK, Nishiyama H, Konety BR, Wit E, Kapadia E, Nam K, Fijlstra MVS, Boormans JL. Pembrolizumab in Participants with Bacillus Calmette-Guerin-Unresponsive Non-Muscle Invasive Bladder Cancer: 5-Year Follow-up From Cohort a of the Phase 2 Keynote-057 Trial. 23rd Annual Meeting of the Society of Urologic Oncology (SUO), 2022. e-Pub 2022.
Mitra AP, Mokkapati S, Navai N, Kamat AM, McConkey DJ, Dinney CPN. Generation and Validation of a Predictive Urine-Microrna Signature for Intravesical BCG Therapy. 23rd Annual Meeting of the Society of Urologic Oncology (SUO), 2022. e-Pub 2022.
Li R, Steinberg GD, Uchio EM, Lamm DL, Shah P, Kamat AM, Bivalacqua T, Packiam VT, Chisamore MJ, McAdory J, Grandi P, Hnat N, Burke J. CORE1: Phase 2 Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin (BCG). Journal of Clinical Oncology 40(16):4597, 2022. e-Pub 2022.
Basnet A, Kamat AM, Necchi A, Li R, Spiess PE, Grivas P, Agarwal N, Cheng L, Pavlick D, Ross JS, Lin DI, Gjoerup O, Jacob JM, Jamaspishvili T, Bratslavsky G, Gupta S. Clinically advanced urothelial bladder cancer (CAUBC) in young onset bladder cancer (YOUC) patients. 2025 ASCO Genitourinary Cancers Symposium.
Boorjian SA, Narayan VM, Konety BR, Master VA, Shore ND, Kamat AM, Bivalacqua TJ, Kates MR, Montgomery JS, Crispen PL, Steinberg GD, Agarwal PK, Schuckman AK, Karsh LI, Bjurlin MA, Brown GA, Lotan Y, Inman BA, Williams MB, Cookson MS, Chang SS, Kim EH, Sankin AI, Dinney C. A0583: Efficacy of intravesical nadofaragene firadenovec-vncg for patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer. 39th Annual Congress of the European Association of Urology.
Cigliola A, Basnet A, Jacob J, Bratslavsky G, Cheng L, Grivas P, Kamat AM, Spiess PE, Dean P, Lin DI, Ross JS, Necchi A. A0863: Urachal (U) and Non-Urachal (NU) Adenocarcinomas (adenoCA) of the bladder. 39th Annual Congress of the European Association of Urology.
Contieri R, Tan WS, Buffi NM, Lughezzani G, Grajales V, Soloway M, Casale P, Hurle R, Kamat AM. A0742: The international bladder cancer group intermediate-risk non-muscle invasive bladder cancer (IBCG IR-NMIBC) scoring system predicts the need for intervention for patients on active surveillance. 39th Annual Congress of the European Association of Urology.
Spiess PE, Necchi A, Li R, Kamat AM, Grivas P, Gupta S, Agarwal N, Cheng L, Pavlick D, Sokol E, Graf RP, Lin DI, Ross JS, Schrock AB, Quintanilha J, Li G, Mitchell JW, Jacob JM, Basnet A, Bratslavsky G. Frequency and impact of a genome-wide homologous recombination deficiency signature (HRDsig+) on the genomic landscape of clinically advanced penile squamous cell carcinoma (CAPSCC). 2025 ASCO Genitourinary Cancers Symposium.
Basin M, Necchi A, Li R, Spiess PE, Kamat AM, Grivas P, Gupta S, Agarwal N, Cheng L, Pavlick D, Sokol E, Graf RP, Lin DI, Ross JS, Schrock AB, Quintanilha J, Li G, Jacob JM, Basnet A, Bratslavsky G. Frequency and impact of a genome-wide homologous recombination deficiency signature (HRDsig+) on the genomic landscape of clinically advanced urothelial bladder carcinoma (CAUBC). 2025 ASCO Genitourinary Cancers Symposium.
Carriere P, Alhalabi O, Gao J, Shah AY, Campbell MT, Mayo LL, Mohamad O, Hoffman KE, Mok H, Lozano C, Shah SJ, Park RJ, Mcguire SE, Kamat AM, Navai N, Bree KK, Guo CC, Tang C, Choi S, Hassanzadeh C. Metastasis-directed radiotherapy in oligometastatic bladder and upper tract cancer. 2025 ASCO Genitourinary Cancers Symposium.
Narayan VM, Lotan Y, Goulet M, Dauphinee S, Veilleux D, Louis KS, Lazure D, Stevenson S, Bilimoria D, Zamzameer F, Chen X, Sublemontier S, Amirkhani S, Fleet C, Pruthi R, Cheung A, Sullivan JC, Packiam VT, Kamat AM. Mechanism of action and translation to the clinic of detalimogene voraplasmid (EG70). 2025 ASCO Genitourinary Cancers Symposium.
Nadal R, Jacob JM, Bratslavsky G, Basnet A, Ross JS, Lin DI, Gjoerup O, Cheng L, Gupta S, Agarwal N, Spiess PE, Li R, Kamat AM, Necchi A, Grivas P. TP53 Y220C mutations in advanced urothelial bladder cancer (UBC). 2025 ASCO Genitourinary Cancers Symposium.
Joshi S, Chang SS, Dickstein RJ, Jayram G, Shore ND, Liu J, Lotan Y, Satkunasivam R, Schuckman AK, Steinberg GD, Taylor JR, Linback T, Pruthi R, Sullivan JC, Tosone C, Kamat AM. A phase 1/2 study of detalimogene voraplasmid (EG-70) intravesical monotherapy for patients with high-risk non-muscle invasive bladder cancer (NMIBC). 2025 ASCO Genitourinary Cancers Symposium.
Maiorano BA, Cigliola A, Tateo V, Mercinelli C, Pastorino GL, Dizman N, Ebrahimi H, Pal SK, Gupta S, Grivas P, Kamat AM, Spiess PE, Agarwal N, Necchi A. Outcomes of immune-checkpoint inhibitor rechallenge in urothelial carcinoma. 2025 ASCO Genitourinary Cancers Symposium.
Myers A, Tan WS, Grajales V, Hwang H, Bree KK, Navai N, Lee BH, Dinney CPN, Kamat AM. A0739: Challenging the paradigm of BCG unresponsive bladder cancer: Does additional BCG have an effect?. 39th Annual Congress of the European Association of Urology.
Gupta S, Kulkarni G, Necchi A, Shore ND, Dave H, Kapadia E, Zhao Q, Kamat A. P312: Phase 2 KEYNOTE-057 cohort C. 39th Annual Congress of the European Association of Urology.
Myers A, Moussa MJ, Fang AM, Wilson N, Campbell MT, Guo CC, Zhang M, Siefker-Radtke A, Kamat AM, Alhalabi O. A0743: Impact of systemic therapy in clinical T1 small-cell neuroendocrine carcinoma of the bladder. 39th Annual Congress of the European Association of Urology.

Book Chapters

Quek ML, Bivalacqua TJ, Kamat AM, Saieg MA, Sankin AI, Tokuda Y, van Rhijn B. Clinical Management. In: The Paris System for Reporting Urinary Cytology. 2. Springer, Cham, 257-266, 2022.
Ibarra Rovira JJ, Kamat AM, Siefker-Radtke AO, Kundra V. Urothelial Carcinoma (Bladder Cancer and Upper Tracts). In: Oncologic Imaging: a Multidisciplinary Approach. 2. Elsevier, 309-329, 329.e1-329.e4, 2022.

Books (edited and written)

Kamat AM, Black, P. Bladder Cancer. Ed(s) 1. Springer Cham, 2021.

Letters to the Editor

Myers AA, Kamat AM. Reply to Christopher Guske, Seyed Behzad Jazayeri, and Roger Li's Letter to the Editor re: Amanda A. Myers, Wei Shen Tan, Valentina Grajales, et al. Challenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Guerin Have an Effect? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.05.027. Eur Urol, 2024.
Grande E, Birtle AJ, Kamat AM. Re: Thomas Powles, Begona Perez-Valderrama, Shilpa Gupta, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med 2024;390:875-88. Eur Urol, 2024.
Contieri R, Hensley PJ, Kamat AM. Reply to Francesco Montorsi, Giuseppe Rosiello, and Giorgio Gandaglia's Letter to the Editor re: Roberto Contieri, Patrick J. Hensley, Wei Shen Tan, et al. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin or Early Radical Cystectomy. Eur Urol Oncol. 2023;6:590-596. Eur Urol Oncol 7: 301, 2024.
Tan WS, O'Donnell M, Li R, Kamat AM, Packiam VT. Reply to Wen-Wei Sung's Letter to the Editor re: Wei Shen Tan, Ian M. McElree, Facundo Davaro, et al. Sequential Intravesical Gemcitabine and Docetaxel Is an Alternative to Bacillus Calmette-Guerin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.06.011. Eur Urol Oncol, 2023.
Bree, KK, Hensley, PJ, Lobo, N, Brooks, NA, Nogueras Gonzalez, G, Guo, CC, Navai, N, Barton Grossman, H, Dinney, CP, Kamat, A. Reply by Authors. Journal of Urology 208: 290-291, 2022.
Williams SB, Kamat AM. Re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. Eur Urol 2016;69:60-9. Eur Urol.
Kamat AM. To the Editor: Response to Barlow et al, Urol Oncol 2010. Urol Oncol.

Less

Selected Presentations & Talks

Local Presentations

2019. Case Presentations: MIBC. Conference. Case Presentations: MIBC. Houston, TX, US.
2019. Speaker: Challenges and Opportunities in the BCG Shortage Era. Conference. Speaker: Challenges and Opportunities in the BCG Shortage Era. Houston, TX, US.
2018. Speaker: Superficial Bladder Cancer: Surgical and Systemic Approaches. Conference. Speaker: Superficial Bladder Cancer: Surgical and Systemic Approaches. Houston, TX, US.
2018. Panelist: Challenging Surgical Cases. Conference. Panelist: Challenging Surgical Cases. Houston, TX, US.
2018. Superficial to muscle-invasive bladder cancer: Non-muscle invasive bladder cancer: Optimizing surveillance and minimizing. Conference. Superficial to muscle-invasive bladder cancer: Non-muscle invasive bladder cancer: Optimizing surveillance and minimizing. Houston, TX, US.
2008. New Therapies for Superficial Bladder Cancer. Conference. New Therapies for Superficial Bladder Cancer. Houston, TX, US.
2008. Enhancing Intravesical Therapy in Bladder Cancer. Conference. Enhancing Intravesical Therapy in Bladder Cancer. Houston, TX, US.
2007. Optimal Management of T1b Urothelial Carcinoma. Conference. Optimal Management of T1b Urothelial Carcinoma. Houston, TX, US.
2005. Optimizing Intravesical Therapy and Surveillance Strategies for Non-Muscle Invasive Bladder Cancer. Conference. Optimizing Intravesical Therapy and Surveillance Strategies for Non-Muscle Invasive Bladder Cancer. Houston, TX, US.
2005. Upper Tract Transitional Cell Tumors. Conference. Upper Tract Transitional Cell Tumors. Houston, TX, US.
2004. Intravesical therapy: indications and choice of agent. Conference. Intravesical therapy: indications and choice of agent. Houston, TX, US.

Regional Presentations

2024. Bladder: Intermediate Risk Disease: Adjuvant for whom?. Invited. University of Texas 2nd Annual Christopher G. Wood Advances in Urologic Oncology Symposium. Austin, Texas, US.
2023. Improving Quality of TURBT: blue light/enbloc/MRI. Invited. University of Texas Inaugural Christopher G. Wood Advances in Urologic Oncology Symposium. Austin, Texas, US.
2020. Bladder Cancer: BCG and links to COVID-19. Invited. Inaugural Earl W. Clawater Lectureship in Urological Surgery. Galveston, Texas, US.
1999. Retrovirus mediated suicide gene therapy for bladder cancer protects against recurrence in a murine model. Conference. Retrovirus mediated suicide gene therapy for bladder cancer protects against recurrence in a murine model. Hilton Head, SC, US.
1999. Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer. Conference. Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer. Pittsburgh, PA, US.
1997. Tracheal aspirate vs. blind bronchial brush in the diagnosis of ventilator-associated pneumonia in tracheotomized patients. Conference. Tracheal aspirate vs. blind bronchial brush in the diagnosis of ventilator-associated pneumonia in tracheotomized patients. Morgantown, WV, US.

National Presentations

2024. NMIBC: BCG Unresponsive Cancer in 2024. Invited. SUO 25th Annual Meeting: Bladder Cancer Course. Dallas, Texas, US.
2024. Striking a Balance: How much is too much bladder sparing therapy/surveillance?. Invited. BCAN Think Tank. San Diego, California, US.
2024. Setting the stage for trials in NMIBC. Conference. AACR Special Conference on Bladder Cancer: Transforming the Field. Charlotte, North Carolina, US.
2024. Instructional Course: Management of Non-Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems. Conference. AUA Annual Meeting 2024. San Antonio, Texas, US.
2024. PeerView: Harnessing Innovation in Bladder Cancer Care. Conference. AUA Annual Meeting 2024. San Antonio, Texas, US.
2024. Surgical Management of Early-Stage Urothelial Cancer. Invited. MSCO 2024 Spring Conference. Minneapolis, Minnesota, US.
2024. Non-Muscle Invasive Bladder Cancer: State of the Art. Conference. New York GU: 17th Annual Interdisciplinary Prostate Cancer Congress and Other Genitourinary Malignancies. New York City, New York, US.
2024. Bruce Lucas Visiting Professorship. Visiting. Bruce Lucas Visiting Professorship. Lexington, Kentucky, US.
2023. Introduction: Exploring rare variant subtypes of bladder tumors. Conference. BCAN Think Tank 2023. Washington, DC, US.
2023. Instructional Course: Management of Non-Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems. Conference. AUA Annual Meeting 2023. Chicago, IL, US.
2022. Defining NMIBC disease states (focus also on unmet needs of each). Conference. Defining NMIBC disease states (focus also on unmet needs of each). Virtual Meeting, US.
2022. Speaker: Intermediate Risk: Trials and Horizons. Conference. SUO Annual Meeting 2022. San Diego, CA, US.
2022. Instructional Course Faculty: Management of Non Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems. Conference. AUA Annual Meeting 2022. New Orleans, LA, US.
2022. Poster: Timing of Radical Cystectomy for BCG Failure. Conference. AUA Annual Meeting 2022. New Orleans, LA, US.
2022. Poster: Urine microRNAs as liquid biopsy assay for predicting response to intravesical BCG therapy. Conference. AUA Annual Meeting 2022. New Orleans, LA, US.
2022. Poster: Management, Surveillance Patterns, and Costs Associated With Low-Grade Ta Non-Muscle Invasive Bladder Cancer. Conference. AUA Annual Meeting 2022. New Orleans, LA, US.
2022. Podium Session Moderator: Bladder Cancer: Non-invasive I. Conference. AUA Annual Meeting 2022. New Orleans, LA, US.
2021. Moderator: Challenges in Clinical Staging of MIBC and Utility of Re-Staging TURBT Prior to and Following Neoadjuvant Therapy?. Conference. SUO Bladder Cancer Course. Orlando, FL, US.
2021. Speaker: Risk Stratification, BCG-Unresponsive and Definitions of Disease States. Conference. FDA Workshop: Clinical Trial Design for Non-Muscle Invasive Bladder Cancer (NMIBC). Silver Spring, MD, US.
2021. Speaker: COVID-19 Vaccine: A Journey to a Post-Pandemic World. Conference. AUA Annual Meeting 2021, MD, US.
2021. Podium Session Moderator : Bladder Cancer: Non-invasive I. Conference. AUA Annual Meeting 2021. Las Vegas, NV, US.
2021. Speaker: Responding to COVID-19: Key Insights from Johnson & Johnson. Conference. AUA Annual Meeting 2021, MD, US.
2021. Instructional Course Faculty: Management of Non Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems. Conference. AUA Annual Meeting 2021, MD, US.
2021. Speaker: What Urologists Want to Know: Addressing Current Questions and Controversies in the Management of Bladder Cancer. Conference. AUA Annual Meeting 2021, MD, US.
2021. Virtual Debate Speaker: Standard TURB or office fulguration or active surveillance for small papillary recurrence in the bladder? Are hospital urologists really necessary?. Conference. 36th Annual EAU Congress 2021 - Virtual, US.
2021. Chair: Poster Session 25: NMIBC: New insights for the diagnosis, management and follow-up. Conference. 36th Annual EAU Congress 2021 - Virtual, US.
2021. Virtual Speaker: Urinary biomarkers: Are we there yet?. Conference. 36th Annual EAU Congress 2021 - Virtual, US.
2021. Virtual Speaker: Defining Intermediate-Risk and High-Risk NMIBC: Test Your Knowledge. Conference. 36th Annual EAU Congress 2021 - Virtual, US.
2021. Virtual Speaker: Best Practices and Expert Insights for Intermediate-Risk NMIBC: Clinical Cases. Conference. 36th Annual EAU Congress 2021 - Virtual, US.
2020. Panel Chair: Career Development Bladder Cancer (CD-BlaC). Conference. Panel Chair: Career Development Bladder Cancer (CD-BlaC), US.
2020. Management of BCG Unresponsive Disease (Virtual Program). Conference. Management of BCG Unresponsive Disease (Virtual Program), US.
2020. What to do in times of BCG Shortage (Virtual Program). Conference. What to do in times of BCG Shortage (Virtual Program), US.
2020. Speaker: Bladder Preservation in Advanced Disease. Conference. 2020 AUA-JHU GBCI Bladder Cancer Research Symposium. Baltimore, MD, US.
2019. Speaker: Immunotherapy for Urothelial Cancers: What does the Urologist need to know?. Conference. TUS Annual Meeting 2019. San Francisco, CA, US.
2019. Debate: Blue Light. Conference. TUS Annual Meeting 2019. San Francisco, CA, US.
2019. Poster: Contemporary Outcomes of Non-Muscle Invasive Bladder Cancer Patients Treated with Induction BCG. Conference. AUA Annual Meeting 2019. Chicago, IL, US.
2019. Satellite Symposium/Speaker: Expert Exchange: Examining the Use of Checkpoint Inhibitors in Bladder Cancer. Conference. AUA Annual Meeting 2019. Chicago, IL, US.
2019. Podium Session Moderator : Bladder Cancer: Non-invasive I. Conference. AUA Annual Meeting 2019. Chicago, IL, US.
2019. Speaker: Management of Non Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems. Conference. AUA Annual Meeting 2019. Chicago, IL, US.
2019. Abstract: The Impact of Neoadjuvant Chemotherapy for Squamous Histology in Patients with Muscle Invasive Bladder Cancer. Conference. AUA Annual Meeting 2019. Chicago, IL, US.
2019. Invited Panelist: FDA Workshop on Bladder Cancer. Importance of TURT in pT0. Conference. Panelist: FDA Workshop on Bladder Cancer. Importance of TURT in pT0. Washington DC, DC, US.
2019. Faculty Speaker: Quality Indicators and Enhanced Imaging in Cystoscope and TURBT. Conference. Faculty Speaker: Quality Indicators and Enhanced Imaging in Cystoscope and TURBT. St. Louis, MO, US.
2019. Abstract: Bacillus Calmette-Guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction: phase 3 KEYNOTE-676 study. Conference. Genitourinary Cancers Symposium 2019. San Francisco, CA, US.
2018. Poster: Natural History of Early High-Grade BCG Failure in Patients who Continue Therapy in EORTC Trial 30962. Conference. SUO Annual Meeting 2018. Phoenix, AZ, US.
2018. Abstract: Phase 2 Study of Pembrolizumab Monotherapy for High-Risk, Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG): Results from Keynote -057. Conference. SUO Annual Meeting 2018. Phoenix, AZ, US.
2018. Poster: Contemporary Outcomes of Non-muscle Invasive Bladder Cancer Patients Treated with BCG. Conference. SUO Annual Meeting 2018. Phoenix, AZ, US.
2018. Poster: Population-based Survival Outcomes and Treatment Costs Comparing Radical Cystectomy with Trimodal Therapy for Patients Diagnosed with Localized Muscle-Invasive Bladder Cancer. Conference. SUO Annual Meeting 2018. Phoenix, AZ, US.
2018. Presenter: Is There An Optimal TURBT Technique, and the Color War?. Conference. LUGPA Annual CME Program 2018. Chicago, IL, US.
2018. Should Variant Histology Change Management of Bladder Cancer?. Conference. Should Variant Histology Change Management of Bladder Cancer?. Seoul.
2018. Speaker: A New Paradigm in Urothelial Cancer: The Convergence of Immuno-oncology & Urology. Conference. AUA Annual Meeting 2018. San Francisco, CA, US.
2018. Podium: BCG Unresponsive Definition Supersedes Distinction between Refractory and Relapsing Disease. Conference. AUA Annual Meeting 2018. San Francisco, CA, US.
2018. Moderator: Immune Checkpoint Inhibitors in Urologic Cancer. Conference. KUA Program at AUA Annual Meeting 2018. San Francisco, CA, US.
2018. Speaker: Management of Non Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems. Conference. AUA Annual Meeting 2018. San Francisco, CA, US.
2018. Plenary: Prime Time Surgical Techniques: Bladder Cancer Program showcasing a video of your technique using Blue Light Cystoscopy (from 2017). Conference. AUA 2018 Annual Meeting. San Francisco, CA, US.
2018. Poster: Importance of maintenance BCG inclusion for the BCG unresponsive classification. Conference. AUA Annual Meeting 2018. San Francisco, CA, US.
2018. Discussion Leader: "Low and Intermediated Risk". Conference. “Biology and Therapy of Non-Muscle Invasive Bladder Cancer: A Johns Hopkins Greenberg Bladder Cancer Institute/American Urological Association Translational Research Collaboration”. Baltimore, MD, US.
2018. Speaker: Clinical Trials for NMIBC. Conference. 2nd Annual International Bladder Cancer Update (IBCU2). Beaver Creek, CO, US.
2017. Chair Panelist. Conference. 2017 Peer Review Cancer Research Program (PRCRP). Reston, VA, US.
2017. Panelist: What radiographic criteria should be used to include patients on adjuvant trials and define recurrent disease in bladder cancer, and what is the role of biopsy?. Conference. FDA, NCI and SUO. Bethesda, MD, US.
2017. Moderator: How can we better categorize bladder cancer patients and enrich patient populations for clinical trials in bladder cancer?. Conference. FDA, NCI and SUO. Bethesda, MD, US.
2017. Clinical Trials in Bladder Cancer. Conference. Future Directions in Urology. Colorado Springs, CO, US.
2017. Guidelines for Management of Muscle Invasive Bladder Cancer: : 2017. Conference. Guidelines for Management of Muscle Invasive Bladder Cancer: : 2017. Boston, MA, US.
2017. Course: Management of NMIBC. Conference. Course: Management of NMIBC. Boston, MA, US.
2017. Tumor Board: Featured Plenary Session. Conference. Tumor Board: Featured Plenary Session. Boston, MA, US.
2017. Management of T1HG Bladder Cancer. Conference. Management of T1HG Bladder Cancer. London, US.
2017. Inaugural Albert Lectureship in Bladder Cancer. Invited. Inaugural Albert Lectureship in Bladder Cancer. Kansas City, Missouri, US.
2017. BCG Response Prediction. Conference. BCG Response Prediction. London, US.
2016. Tumor Board. Conference. Tumor Board. Colorado Springs, US.
2016. KEYNOTE-057: Phase 2 study of pembrolizumab for patients with BCG -unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC). Conference. KEYNOTE-057: Phase 2 study of pembrolizumab for patients with BCG -unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC). Chicago, US.
2016. Bladder Cancer Course. Conference. Bladder Cancer Course. San Diego, US.
2016. BCG Failure - Options for Therapy. Conference. BCG Failure - Options for Therapy, US.
2015. What is the Best Approach to Radical Cystectomy. Conference. What is the Best Approach to Radical Cystectomy. Scottsdale, AZ, US.
2015. Definitions and Endpoints in NMI Bladder Cancer. Conference. Definitions and Endpoints in NMI Bladder Cancer. Bethesda, US.
2015. Multimodal Management of Bladder Cancer. Conference. Multimodal Management of Bladder Cancer. Orlando, US.
2014. Immunotherapy for Bladder Cancer - Panel Chair. Conference. Immunotherapy for Bladder Cancer - Panel Chair. San Diego, US.
2014. Predicting Response to Immunotherapy for Bladder Cancer (BCG). Conference. Predicting Response to Immunotherapy for Bladder Cancer (BCG). Orlando, US.
2014. Personalized Medicine for Bladder Cancer. Conference. Personalized Medicine for Bladder Cancer. Kobe, US.
2013. Robotic Radical Cystectomy versus Open Radical Cystectomy. Conference. Robotic Radical Cystectomy versus Open Radical Cystectomy. Houston, US.
2013. Best of AUA - Bladder Cancer & Testis Cancer. Conference. AUA. Tokyo, US.
2013. Early Cystectomy for Micropapillary Bladder Cancer. Conference. Early Cystectomy for Micropapillary Bladder Cancer. San Diego, US.
2013. Optimizing BCG for Bladder Cancer. Conference. Optimizing BCG for Bladder Cancer. San Diego, CA, US.
2013. Urothelial Carcinomas: Multimodal Management Of Difficult Cases. Conference. Urothelial Carcinomas: Multimodal Management Of Difficult Cases. Orlando, US.
2012. Optimizing Recovery from Cystectomy: Results from the Phase III Alvimopan Trial. Conference. Optimizing Recovery from Cystectomy: Results from the Phase III Alvimopan Trial. Bethesda, US.
2010. Common Challenges in Non Muscle Invasive Bladder Cancer. Conference. Common Challenges in Non Muscle Invasive Bladder Cancer. San Francisco, CA, US.
2010. Optimizing BCG Therapy: Role of Inflammation and Cytokine Biomarkers. Conference. Optimizing BCG Therapy: Role of Inflammation and Cytokine Biomarkers. San Francisco, CA, US.
2009. Novel Surgical Therapy for Bladder Cancer. Conference. Novel Surgical Therapy for Bladder Cancer. Park City, UT, US.
2008. Cardiac history and risk of post-cystectomy cardiac complications. Conference. Cardiac history and risk of post-cystectomy cardiac complications. San Francisco, CA, US.
2007. Management of Ta, T1 Bladder Tumors and Case Discussion. Conference. Management of Ta, T1 Bladder Tumors and Case Discussion. Chicago, IL, US.
2007. Surgical Treatment of Renal Cell Carcinoma. Conference. Surgical Treatment of Renal Cell Carcinoma. Santa Barbara, CA, US.
2007. Management of Bladder Cancer. Conference. Management of Bladder Cancer. Santa Barbara, CA, US.
2007. Optimal Management of Ta, T1 and CIS bladder cancer using intravesical therapy. Conference. Optimal Management of Ta, T1 and CIS bladder cancer using intravesical therapy. Chicago, IL, US.
2006. Management of Advanced Bladder Cancer. Conference. Management of Advanced Bladder Cancer. Atlanta, GA, US.
2006. Smac Mimetics: Application in Bladder Cancer Therapy. Conference. Smac Mimetics: Application in Bladder Cancer Therapy. Baltimore, MD, US.
2005. Management of Superficial Bladder Cancer. Conference. Management of Superficial Bladder Cancer. Bethesda, MD, US.
2005. The Case for Early Cystectomy in Non-Muscle-Invasive Micropapillary Transitional Cell Carcinoma of the Bladder. Conference. The Case for Early Cystectomy in Non-Muscle-Invasive Micropapillary Transitional Cell Carcinoma of the Bladder. San Antonio, TX, US.
2005. Micropapillary Transitional Cell Carcinoma of the Bladder: A Retrospective Review of the Experience with 100 Consecutive Patients. Conference. Micropapillary Transitional Cell Carcinoma of the Bladder: A Retrospective Review of the Experience with 100 Consecutive Patients. San Antonio, TX, US.
2004. Combination Therapy using BCG with Novel Agents. Conference. Combination Therapy using BCG with Novel Agents. Miami, FL, US.
2003. Antitumor activity of common antibiotics against superficial bladder cancer. Conference. Antitumor activity of common antibiotics against superficial bladder cancer. Chicago, IL, US.
2003. Fluctuation of greater than 1.5 ng/ml in serum PSA more than 2 years after externalbeam radiotherapy predicts for biochemical failure. Conference. Fluctuation of greater than 1.5 ng/ml in serum PSA more than 2 years after externalbeam radiotherapy predicts for biochemical failure. Chicago, IL, US.
2002. CI-1033, a pan-erbB tyrosine kinase antagonist, inhibits the growth of orthotopic bladder cancer tumors via direct effects on receptor phosphorylation and inhibition of angiogenesis. Conference. CI-1033, a pan-erbB tyrosine kinase antagonist, inhibits the growth of orthotopic bladder cancer tumors via direct effects on receptor phosphorylation and inhibition of angiogenesis. Bethesda, MD, US.
2002. Retrovirus mediated suicide gene therapy protects against tumor rechallenge in a murine bladder cancer model. Conference. Retrovirus mediated suicide gene therapy protects against tumor rechallenge in a murine bladder cancer model. San Francisco, CA, US.
2002. The proteasome inhibitor PS-341 sensitizes drug-refractory human transitional cell tumors to gemcitabine. Conference. The proteasome inhibitor PS-341 sensitizes drug-refractory human transitional cell tumors to gemcitabine. San Francisco, CA, US.
1999. Suicide gene therapy for bladder cancer using retrovirus mediated delivery in a murine model. Conference. Suicide gene therapy for bladder cancer using retrovirus mediated delivery in a murine model. Dallas, TX, US.
1999. Cytotoxic effect of Nerium oleander extract on bladder cancer cells. Conference. Cytotoxic effect of Nerium oleander extract on bladder cancer cells. Dallas, TX, US.
1999. Cytotoxic effect of Nerium oleander extract on bladder cancer cells. Conference. Cytotoxic effect of Nerium oleander extract on bladder cancer cells. Atlanta, GA, US.
1998. Cytotoxic effect of Nerium oleander extract on bladder cancer cells. Conference. Cytotoxic effect of Nerium oleander extract on bladder cancer cells. Prouts Neck, ME, US.

International Presentations

2024. Ongoing studies from abroad: Updates from IBCG-IBCN. Invited. San Raffaele Urologic Oncology Retreat 3rd Edition 2024. Milan, IT.
2024. How shall we envision a therapeutic journey for a patient with bladder cancer – geography vs. scientific evidence. Invited. San Raffaele Urologic Oncology Retreat 3rd Edition 2024. Milan, IT.
2024. Panel: MIBC - Optimization of neoadjuvant and adjuvant therapy. Invited. Apollo Cancer Conclave 2024. Mumbai, IN.
2024. Keynote: Challenges in BCG therapy with an overview of alternative strategies. Invited. Apollo Cancer Conclave 2024. Mumbai, IN.
2024. Visiting Professor in Urologic Oncology. Visiting. Mumbai, IN.
2024. Tricks to Avoid the Urinary Leak and Ureteric Strictures. Conference. 44th Congress of the Société Internationale d'Urologie (SIU). New Delhi, IN.
2024. IBCG Master Class in NMIBC: Understanding Nuances of Risk Stratification and Appropriate Patient Selection for NMIBC Treatments. Conference. 44th Congress of the Société Internationale d'Urologie (SIU). New Delhi, IN.
2024. IBCG Master Class in NMIBC: Case Based Learning Examples with Audience Participation. Invited. 44th Congress of the Société Internationale d'Urologie (SIU). New Delhi, IN.
2024. Bladder Preservation in MIBC: Recommendations from the International Bladder Cancer Group (IBCG). Conference. World Urological Oncology Federation (WUOF) Symposium: Advancing Science for Improving Patient Care. New Delhi, IN.
2024. Unmet need in bladder cancer: next generation clinical trials. Invited. Urology Course 57th Edition. Barcelona, ES.
2024. Rapid-fire debate: Bladder preservation in MIBC - results and costs. Invited. Urology Course 57th Edition. Barcelona, ES.
2024. Challenge the experts: Clinical cases. Invited. Urology Course 57th Edition. Barcelona, ES.
2024. Semi-Live Surgery: My TURBT in 2024. Invited. Urology Course 57th Edition. Barcelona, ES.
2024. Introduction & Opening Statements. IBCG 2024 Annual Retreat. Houston, US.
2024. Managing High-Risk vs Very High-Risk NMIBC: Best Practice and Clinical Considerations. Conference. 39th Annual Congress of the European Association of Urology. Paris, FR.
2024. Rapid Fire Debate 3: Healthy Patient with T1HG Micropapillary NMIBC - What is the best treatment option? What if mixed histologic subtypes in addition to micropapillary?. Conference. 39th Annual Congress of the European Association of Urology. Paris, FR.
2024. Treatment landscape of BCG-unresponsive NMIBC. Invited. CUHKMC Uro-Oncology Symposium. Hong Kong, CN.
2024. Visiting Professorship in Bladder Cancer. Visiting. CHIFAE 6th Edition Onco-Urology Congress. Fes, MA.
2023. Academic Bladder Cancer Research. Invited. Singapore General Hospital (SGH) 35th Anniversary Scientific Program. Singapore, SG.
2023. Systemic versus intravesical drug from high-risk NMIBC naive to BCG. Invited. 15th EMUC Congress. Marseille, FR.
2023. Challenges in the Management of Non-Muscle Invasive Bladder Urothelial Cancer. Invited. 43rd Congress of the Société Internationale d'Urologie (SIU). Istanbul, TR.
2023. Nuances of Diagnosis and Management of Intermediate Risk NMIBC. Invited. WUOF 2023 Conference. Istanbul, TR.
2023. The Changing Face of Surgical Management of Bladder Cancer. Invited. British Uro-Oncology Group 20th Annual Meeting. London, GB.
2023. Introduction & Opening Statements. IBCG 2023 Annual Retreat. Houston, US.
2023. KeyNote Speaker: Nuances of Risk Stratification for NMIBC: What do we need to know in 2023?. Conference. Urological Society of India, IN.
2023. Moderator: Rapid Fire Discussions. Conference. Chilean Society of Urology Annual Course 2023. Santiago, CL.
2023. KeyNote Speaker: What has changed in the management of Bladder Cancer? Lessons learnt in the last three decades. Conference. Chilean Society of Urology Annual Course 2023. Santiago, CL.
2023. Speaker: Optical Enhanced Diagnosis and TURBT for Bladder Cancer. Conference. International Congress of Uro-Oncology Multiprofessional Symposium 2023. Sao Paulo, BR.
2023. Speaker: The state of the art of radical cystectomy: practical tips to optimize outcomes. Conference. International Congress of Uro-Oncology Multiprofessional Symposium 2023. Sao Paulo, BR.
2023. Speaker: Intermediate Risk NMIBC: Definitions and Strategies. Conference. International Congress of Uro-Oncology Multiprofessional Symposium 2023. Sao Paulo, BR.
2023. Speaker: BCG Unresponsive NMIBC: Systemic Therapy or Intravesical Therapy?. Conference. International Congress of Uro-Oncology Multiprofessional Symposium 2023. Sao Paulo, BR.
2023. Session Chair: Thematic Session: Rapid-fire debates: Common problems and controversies in bladder cancer. Conference. EAU Congress 2023. Milan, IT.
2023. Speaker: Meeting of the EAU Section of Oncological Urology (ESOU): Progress and controversies in oncological urology - The evolving landscape in the management of high-risk non-muscle-invasive bladder cancer. Conference. EAU Congress 2023. Milan, IT.
2022. Speaker: The Experience of the International Bladder Cancer Network (IBCN). Conference. San Raffaelle Urologic Oncology Retreat. Milan, IT.
2022. Speaker: Instructional Course: IBCG Master Class on BCG (and Beyond). Conference. 42nd Congress of the Société Internationale d'Urologie (SIU). Montreal, CA.
2022. Lecture in Urologic Oncology. Conference. Lecture in Urologic Oncology. Cork, IE.
2021. Speaker: Patient Involvement in Bladder Cancer Research. Conference. World Bladder Cancer Patient Forum 2021 – Virtual Event, GB.
2019. Invited Speaker: Alternatives to BCG for Bladder Cancer. Conference. 11th European Multidisciplinary Congress on Urological Cancers. Vienna, AT.
2019. Invited Speaker: Discussant for KN057 Trial of Pembrolizumab in BCG Unresponsive Bladder Cancer. Conference. 11th European Multidisciplinary Congress on Urological Cancers. Vienna, AT.
2019. Moderator: Panel: Case-based Management of Upper Tract Urothelial Carcinoma. Conference. 39th Congress of the Société Internationale d’Urologie. Athens, GR.
2019. Master Class 07— Muscle-Invasive Bladder Cancer: Surgical Aspects. Conference. 39th Congress of the Société Internationale d’Urologie. Athens, GR.
2019. Instructional Course 09: Management of Non-Muscle Invasive Bladder Cancer (NMIBC) - Are We Doing the Right Thing? "Are We Over Indulging in Restaging TURBT". Conference. 39th Congress of the Société Internationale d’Urologie. Athens, GR.
2019. Keynote Speaker: Optimal Management of Bladder Cancer. Conference. XII Jornadas Filial Norte 2019. Antofagasta, CL.
2019. Speaker: Implications of Variant Histology in Bladder Cancer, Intravesical therapy - Myths and Mysteries of BCG. Conference. USANZ 2019. Brisbane, AU.
2019. Speaker: Biomarkers for IO therapy in Bladder Cancer (OR) – IOs in Bladder Cancer – Role of the Urologist. Conference. USANZ 2019. Brisbane, AU.
2019. Speaker: Is robotic cystectomy actually worth it?. Conference. USANZ 2019. Brisbane, AU.
2019. Speaker: Role of FISH in Bladder Cancer. Conference. JUA Annual Meeting. Nagoya, JP.
2019. Speaker: Genomic classification of bladder and variant cancer. Conference. USANZ 2019. Brisbane, AU.
2019. Speaker: Micropapillary bladder cancer - MD Anderson approach. Conference. USANZ 2019. Brisbane, AU.
2019. Speaker: Immune therapy in bladder cancer - standard of care?. Conference. USANZ 2019. Brisbane, AU.
2019. Speaker: Specialty Session: EAU Guidelines controversies - part I NMIBC: Should a TUR be done in all bladder tumors?. Conference. EAU Congress 2019. Barcelona, ES.
2019. Plenary Session: Beyond BCG in non-muscle invasive bladder cancer. Conference. EAU Congress 2019. Barcelona, ES.
2019. Specialty Session: Common problems in muscle-invasive and advanced bladder cancer: Evidence based debates:. Conference. EAU Congress 2019 (EAU). Barcelona, ES.
2019. Speaker: Enhanced Recovery Pathways for Radical Cystectomy Patients & Enhanced Optical Cystoscopy and Tumor Resection with Blue Light Technology. Conference. Apollo Cancer Conclave 2019. Chennai, IN.
2018. Bladder Cancer Hot Topics - 4 Separate Talks. Conference. Bladder Cancer Hot Topics - 4 Separate Talks. Acapulco, MX.
2018. Speaker: Immunotherapy in non-muscle invasive urothelial bladder. Conference. EAU Update on Bladder Cancer 2018. Munich, DE.
2018. Chair of Specialty Session: Common Problems in Bladder Cancer; Evidence Based Debates. Conference. 33rd Annual EAU Congress 2018. Copenhagen, DK.
2018. Invited Speaker: Bladder: Optimal management of T1HG bladder cancer, Options for bladder salvage after failure of BCG immunotherapy. Management of variant histology bladder cancer, Clinical Cases: Localized and locally advanced bladder cancer. Conference. IX International Congress of Uro-Oncology. Sao Paulo, BR.
2017. Invited Speaker. Conference. 7th Shanghai International Genitourinary Oncology Symposium. Shanghai, CN.
2017. The Buck Stops Here - Difficult Cases Simplified by Dr Kamat. Conference. The Buck Stops Here - Difficult Cases Simplified by Dr Kamat. Goa, IN.
2017. Management of Complex Bladder Cancer. Conference. Management of Complex Bladder Cancer. Santiago, CL.
2017. Variant Histologies in Bladder Cancer. Conference. Variant Histologies in Bladder Cancer. Santiago, CL.
2016. Neoadjuvant Chemotherapy for Bladder Cancer. Conference. Neoadjuvant Chemotherapy for Bladder Cancer. Buenos Aires, AR.
2016. Radical Cystectomy: Decreasing Readmission Rates. Conference. Radical Cystectomy: Decreasing Readmission Rates. Buenos Aires, AR.
2016. Moderator: New Therapies and Diagnoses in Bladder Cancer. Conference. Moderator: New Therapies and Diagnoses in Bladder Cancer. Buenos Aires, AR.
2016. AUA Featured Lecture on Bladder Cancer. Conference. AUA Featured Lecture on Bladder Cancer. Sendai, JP.
2016. Key Note Lecture on Bladder Cancer. Conference. Key Note Lecture on Bladder Cancer. Sendai, JP.
2016. Efficacy of Mycobaterial Cell Wall Nucleic Acid Complex in BCG Unresponsive Patients. Conference. Efficacy of Mycobaterial Cell Wall Nucleic Acid Complex in BCG Unresponsive Patients. Munich, DE.
2016. BCG Failure: Standardized Definition and Options for Management. Conference. BCG Failure: Standardized Definition and Options for Management. Munich, DE.
2016. Bladder Cancer: Various Topics (4 lectures). Conference. Bladder Cancer: Various Topics (4 lectures). Sao Paulo, BR.
2015. Debate: Radical Cystectomy and Robotic Cystectomy. Conference. Debate: Radical Cystectomy and Robotic Cystectomy. Cancun, MX.
2015. Radical Cystectomy - Step by Step Instructional Course. Conference. Radical Cystectomy - Step by Step Instructional Course. Cancun, MX.
2015. Tissue Based Studies in Bladder Cancer. Conference. Tissue Based Studies in Bladder Cancer. Athens, GR.
2015. Robotic Radical Prostatectomy - Step by Step. Conference. Robotic Radical Prostatectomy - Step by Step. Mumbai, IN.
2015. What to do in times of BCG Shortage?. Conference. What to do in times of BCG Shortage?. Madrid, ES.
2014. Optimal Selection of Patients for Neoadjuvant Chemotherapy of Bladder Cancer. Conference. Optimal Selection of Patients for Neoadjuvant Chemotherapy of Bladder Cancer. Glasgow, GB.
2014. Guest Speaker, 2nd Annual American Urological Association. Conference. Guest Speaker, 2nd Annual American Urological Association. Abu Dhabi, AE.
2014. Annual Review Course, Oncology. Conference. Annual Review Course, Oncology. Cairo, EG.
2014. Photodynamic Diagnosis of Bladder Cancer. Conference. Photodynamic Diagnosis of Bladder Cancer. Kobe, JP.
2014. Managing Patients with NMIBC: How can we improve?. Conference. Managing Patients with NMIBC: How can we improve?. Stockholm, SE.
2013. Optimizing Quality of Care for Muscle Invasive Bladder Cancer. Conference. Optimizing Quality of Care for Muscle Invasive Bladder Cancer. Vancouver, CA.
2012. Optimizing BCG Therapy for Bladder Cancer: When and How?. Conference. Optimizing BCG Therapy for Bladder Cancer: When and How?. Fukuoka, JP.
2011. Urooncologic Fellowship Programs and Reflections In America: What Should I Do To Be A Fellow?. Conference. Urooncologic Fellowship Programs and Reflections In America: What Should I Do To Be A Fellow?, TR.
2011. International Consultation on Urologic Diseases - Bladder Cancer Guidelines. Conference. International Consultation on Urologic Diseases - Bladder Cancer Guidelines. Vienna, AT.
2010. Role of Re-TUR in management of T1 disease. Conference. Role of Re-TUR in management of T1 disease. Mumbai, IN.
2010. Intravesical Therapy for Bladder Cancer - State of the Art. Conference. Intravesical Therapy for Bladder Cancer - State of the Art. Mumbai, IN.
2009. Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancer. Conference. Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancer. Shanghai, CN.
2008. Chemoprevention of Bladder Cancer. Conference. Chemoprevention of Bladder Cancer. Montreal, CA.
2007. Key Note: Bladder Cancer Management. Conference. Key Note: Bladder Cancer Management. Patna, IN.
2007. State of the Art in Intravesical Therapy. Conference. State of the Art in Intravesical Therapy. Montreal, CA.

Formal Peers

2023. Visiting Professor: Bladder Cancer Research. Invited. Visiting Professor: Bladder Cancer Research. Torino, IT.
2022. Visiting Professor. Invited. Visiting Professor. London, GB.
2022. Intravesical BCG: Update on "State of the Art". Invited. Intravesical BCG: Update on "State of the Art". New York, NY, US.
2022. Visiting Professor: Intravesical BCG: Update on "State of the Art". Invited. Visiting Professor: Intravesical BCG: Update on "State of the Art". New York, NY, US.
2021. Visiting Professor (Virtual): The Multidisciplinary Bladder Cancer Clinic (MDBCC): A precision, personalized approach to bladder cancer management. Invited. Visiting Professor (Virtual): The Multidisciplinary Bladder Cancer Clinic (MDBCC): A precision, personalized approach to bladder cancer management. Toronto, Ontario, CA.
2021. VP: Optimal Management of T1HG Bladder Cancer. Invited. VP: Optimal Management of T1HG Bladder Cancer. Louisville, KY, US.
2021. VP: Diagnosis and Management of BCG Unresponsive Non-muscle Invasive Bladder Cancer. Invited. VP: Diagnosis and Management of BCG Unresponsive Non-muscle Invasive Bladder Cancer. Tampa, FL, US.
2020. Bladder Cancer - BCG and Links to COVID19. Invited. Bladder Cancer - BCG and Links to COVID19. Galveston, TX, US.
2020. Guest Lecture: BCG and Covid. Invited. Guest Lecture: BCG and Covid. Albany, NY, US.
2019. Visiting Professor: Use of Optical Enhanced Technology in Bladder Cancer. Invited. Visiting Professor: Use of Optical Enhanced Technology in Bladder Cancer. Houston, TX, US.
2018. Optimal TURBT Technique. Invited. Optimal TURBT Technique. Chicago, US.
2018. Options for Patients Failing BCG Therapy. Invited. Options for Patients Failing BCG Therapy. Houston, TX, US.
2018. Blebbishield Emergency Program Overrides Chromosomal Instability and Phagocytosis Checkpoints in Cancer Stem Cells. Invited. Blebbishield Emergency Program Overrides Chromosomal Instability and Phagocytosis Checkpoints in Cancer Stem Cells. Honolulu, HI, US.
2018. Invited Speaker: BCG Responsive Disease Topic: "Predicting BCG Efficacy". Invited. Invited Speaker: BCG Responsive Disease Topic: "Predicting BCG Efficacy". Baltimore, MD, US.
2017. FDA-NCI Public Workshop on Considerations in Adjuvant Trials in Bladder and Kidney Cancer. Invited. FDA-NCI Public Workshop on Considerations in Adjuvant Trials in Bladder and Kidney Cancer. Bethesda, MD, US.
2017. Bladder Cancer 2017. Invited. Bladder Cancer 2017. Kansas, KS, US.
2017. Inaugural Visiting Professor - Albert Lectureship. Invited. Inaugural Visiting Professor - Albert Lectureship. Kansas, MO, US.
2017. Surgical Tips and Tricks - Radical Cystectomy. Invited. Surgical Tips and Tricks - Radical Cystectomy. Santiago, CL.
2016. AUA Guest Lecture: Predicting Response to Immunotherapy for Cancer. Invited. AUA Guest Lecture: Predicting Response to Immunotherapy for Cancer. Sendai, JP.
2016. Management of Bladder Cancer. Invited. Management of Bladder Cancer. Sao Paulo, BR.
2016. Management of BCG Unresponsive Patients. Invited. Management of BCG Unresponsive Patients. Munich, DE.
2015. Advances in Prostate Cancer & Bladder Cancer. Invited. Advances in Prostate Cancer & Bladder Cancer. Mumbai, IN.
2015. Bladder Cancer. Invited. Bladder Cancer, NY, US.
2014. Personalized Medicine for Urothelial Cancer. Invited. Personalized Medicine for Urothelial Cancer. Morgantown, West Virginia, US.
2013. Complex Surgery (Neobladder) in Bladder Cancer. Invited. Complex Surgery (Neobladder) in Bladder Cancer. Santiago, CL.
2012. Personalized Medicine in Bladder Cancer. Invited. Personalized Medicine in Bladder Cancer. Kagawa, JP.
2012. Brady Urology Grand Rounds Conferences: Tailored Therapy for Bladder Cancer: 2012. Invited. Brady Urology Grand Rounds Conferences: Tailored Therapy for Bladder Cancer: 2012. New York, NY, US.
2012. Management of Non Muscle Invasive Bladder Cancer. Invited. Management of Non Muscle Invasive Bladder Cancer. Tokyo, Tokyo, JP.
2012. Cases Discussion in Localized Prostate Cancer. Invited. Cases Discussion in Localized Prostate Cancer. New Delhi, India, IN.
2012. Management of Bladder Cancer. Invited. Management of Bladder Cancer. St Louis, MO, US.
2011. 2011 Update on Management of Non-Muscle Invasive Bladder Cancer. Invited. 2011 Update on Management of Non-Muscle Invasive Bladder Cancer. Nashville, TN, US.
2010. What's New in Management of Non-Muscle Invasive Bladder Cancer. Invited. What's New in Management of Non-Muscle Invasive Bladder Cancer. Oklahoma City, OK, US.
2009. Surgical Therapy for Bladder Cancer. Invited. Surgical Therapy for Bladder Cancer. St. Louis, MO, US.
2009. Challenges in Management of Bladder Cancer. Invited. Challenges in Management of Bladder Cancer. Montreal, CA.
2009. Management of Non Muscle Invasive Bladder Cancer. Invited. Management of Non Muscle Invasive Bladder Cancer. Washington, DC, US.
2008. The Use of BCG to Treat Bladder Cancer. Invited. The Use of BCG to Treat Bladder Cancer. Orlando, FL, US.
2007. Indian American Urologic Association Oration on Bladder Cancer Management. Invited. Indian American Urologic Association Oration on Bladder Cancer Management. Patna, IN.
2007. Bladder Cancer and Penile Cancer Updates. Invited. Bladder Cancer and Penile Cancer Updates. Morgantown, WV, US.
2005. Advances in the Surgical Management of Prostate Cancer. Invited. Advances in the Surgical Management of Prostate Cancer. Istanbul, TR.
2004. Surgical management of Bladder Cancer. Invited. Surgical management of Bladder Cancer. Madrid, ES.
2004. Current role of PSA testing. Invited. Current role of PSA testing. Shreveport, LA, US.
1999. Suicide gene therapy for bladder cancer using retrovirus mediated delivery in a murine model. Invited. Suicide gene therapy for bladder cancer using retrovirus mediated delivery in a murine model. Greenbrier, WV, US.
1996. Fournier's gangrene: Is a colostomy necessary?. Invited. Fournier's gangrene: Is a colostomy necessary?. Morgantown, WV, US.

Less

Grant & Contract Support

Date:	2024 - 2025
Title:	Clinical Risk Stratification of Micropapillary Bladder Cancer
Funding Source:	American Urological Association, Urology Care Foundation
Role:	Mentor

Date:	2016 - 2021
Title:	A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN? (rAd-IFN/Syn3) Administered Intravesically to Patients with High Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
Funding Source:	FKD Therapies Oy
Role:	PI
ID:	2016-0342

Date:	2016 - Present
Title:	Bladder Cancer Stem Cells and Apoptosis Escape Mechanisms
Funding Source:	The Leo & Anne Albert Institute for Bladder Cancer Care and Research
Role:	PI

Date:	2016 - Present
Title:	Bladder Cancer Research and Education
Funding Source:	Coleman Foundation
Role:	PI

Date:	2015 - 2018
Title:	A Phase 1/2, Placebo Controlled, Randomized Study
Funding Source:	Heat Biologics
Role:	PI

Date:	2013 - 2019
Title:	A Phase II, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects with High Grade, BCG Refractory, Relapsed or Non-Muscle Invasive Bladder Cancer (NMIBC)
Funding Source:	FKD Therapies Oy
Role:	PI
ID:	2012-0609

Date:	2012 - 2015
Title:	A Phase II, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAD-IFN/Syn3 Following Intravesical Administration in Subjects with High Grade, BCG Refractory, Relapsed or Non-Muscle Invasive Bladder Cancer (NMIBC)
Funding Source:	FKD Therapies Oy
Role:	PI
ID:	rAd-IFN-CS-002

Date:	2012 - Present
Title:	Bladder Cancer Research and Education
Funding Source:	Maria and Raymond Floyd Family Foundation
Role:	Program Leader

Date:	2010 - 2012
Title:	Lenalidomide
Funding Source:	Celgene Corporation
Role:	PI
ID:	LS2010-00030918JW

Date:	2010 - 2013
Title:	Markers of Response to Intravesical Bladder Cancer Therapy
Funding Source:	Alere, Inc
Role:	PI
ID:	LS2009-00029304JW 02

Date:	2009 - 2012
Title:	Aventis Urologic Oncology Fellowship - Clinical Trials Research
Funding Source:	Hope Foundation
Role:	PI
ID:	01

Date:	2009 - 2011
Title:	A Phase 4 CT, Multicenter, Double-Blind, Placebo-Controled, parallel Study of Alvimopan for the Management of Postoperative Illeus in Subjects Undergoing Radical Cystectomy (Clinical Trial)
Funding Source:	Adolor Corporation
Role:	PI
ID:	CS2009-00027191LG

Date:	2009 - 2019
Title:	A Phase III Blinded Study of Immediate Post-TURBT Instillation of Gemcitabine Versus Saline in Patients with Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer
Funding Source:	SWOG
Role:	PI
ID:	SWOGS0337

Date:	2007 - 2012
Title:	Phase III, Open Label, Multi-Center Study of the Efficacy and Safety of MCC in the Treatment of Patients with Superficial Bladder Cancer at Hight Risk of Progesssion and Who are Refractory to BCG (Part I & II).(Clinical Trial)
Funding Source:	Bioniche Therapeutics Limited
Role:	PI
ID:	CS2007-00020166JW

Date:	2006 - 2011
Title:	GU SPORE Project C - Pathology and data management
Funding Source:	NIH/NCI
Role:	Clinical Co-Leader
ID:	P50 CA091846

Date:	2006 - 2007
Title:	Role of IAPs in Bladder Cancer
Funding Source:	Tetralogic Pharmaceuticals
Role:	PI

Date:	2006 - 2011
Title:	Curcumin in Bladder Cancer
Funding Source:	Clayton Foundation for Research
Role:	PI

Date:	2005 - 2012
Title:	Identifying Surrogate Markers of Treatment Response to Intravesical Immunotherapy for Bladder Cancer
Funding Source:	FAMRI
Role:	PI
ID:	FAMRI 04

Date:	2003 - 2005
Title:	Chemoprevention of Bladder Cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	5 P50 CA091846 03

Date:	2001 - 2013
Title:	GU SPORE Project 2 - Role of MicroRNA in Bladder Cancer Risk and Outcome: A genome-wide
Funding Source:	NIH/NCI
Role:	Clinical Co-Leader
ID:	P50 CA091846

Date:	2001 - 2013
Title:	GU SPORE - Project 1 Targeting FGFR and EGFR in bladder cancer
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	P50 CA091846

Date:	2001 - 2018
Title:	The UT MD Anderson SPORE in Genitourinary Cancer Project 2: Role of MicroRNA in Bladder Cancer Risk and Outcome: A genome-wide analysis
Funding Source:	NIH/NCI
Role:	Co-Program Leader
ID:	PA50 CA091846-14

CV information above last modified April 02, 2025

Ashish M. Kamat, MD, MBBS, FACS

About Dr. Ashish M. Kamat

Present Title & Affiliation

Primary Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Editorials

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Ashish M. Kamat, MD, MBBS, FACS

About Dr. Ashish M. Kamat

Present Title & Affiliation

Primary Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Editorials

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer